Next Article in Journal
SUSSOL—Using Artificial Intelligence for Greener Solvent Selection and Substitution
Next Article in Special Issue
Synthesis and Immunological Evaluation of a Single Molecular Construct MUC1 Vaccine Containing l-Rhamnose Repeating Units
Previous Article in Journal
Evaluation of the Content of Polyphenols, Antioxidant Activity and Physicochemical Properties of Tortillas Added with Bambara Groundnut Flour
Previous Article in Special Issue
Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Chemistry and Biological Activities of 1,2,4-Triazolethiones—Antiviral and Anti-Infective Drugs

1
Chemistry Department, Faculty of Science, Minia University, El-Minia 61519, Egypt
2
Institute of Organic Chemistry, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany
3
Institute of Biological and Chemical Systems (IBCS-FMS), Karlsruhe Institute of Technology, 76344 Eggenstein-Leopoldshafen, Germany
*
Authors to whom correspondence should be addressed.
Molecules 2020, 25(13), 3036; https://doi.org/10.3390/molecules25133036
Submission received: 7 June 2020 / Revised: 24 June 2020 / Accepted: 25 June 2020 / Published: 3 July 2020
(This article belongs to the Special Issue Bioconjugation Strategies in Drug Delivery and Molecular Imaging)

Abstract

:
Mercapto-substituted 1,2,4-triazoles are very interesting compounds as they play an important role in chemopreventive and chemotherapeutic effects on cancer. In recent decades, literature has been enriched with sulfur- and nitrogen-containing heterocycles which are used as a basic nucleus of different heterocyclic compounds with various biological applications in medicine and also occupy a huge part of natural products. Therefore, we shed, herein, more light on the synthesis of this interesting class and its application as a biologically active moiety. They might also be suitable as antiviral and anti-infective drugs.

1. Introduction

Taribavirin (I) (Figure 1) is a triazole based clinically used as antiviral drugs (Figure 1). It is an active agent against a number of DNA and RNA viruses. It is indicated for severe respiratory syncytial virus (RSV) infection, hepatitis C infection, and other viral infections like the West Nile virus and dengue fever [1,2,3]. Taribavirin (also known as viramidine) is an antiviral drug in Phase III human trials, but not yet approved for pharmaceutical use [4].
AIDS is characterized by an abnormal host defense mechanism that predisposes to infections with opportunistic microorganisms [5]. It was reported [6] that compounds IIIad (Figure 1) have been proved as treatment for HIV-1. The viral enzymes, reverse transcriptase (RT), integrase (IN), and protease (PR) are all good drug targets. Two distinct types of RT inhibitors, both of which block the polymerase activity of RT, have been approved to treat HIV-1 infections, nucleoside analogs (NRTIs), and nonnucleosides (NNRTIs), and there are promising leads for compounds that either block the RNase H activity or block the polymerase in other ways. A better understanding of the structure and function(s) of RT and of the mechanism(s) of inhibition can be used to generate better drugs; in particular, drugs that are effective against the current drug-resistant strains of HIV-1.NNRTIs via high throughput screening (HTS) using a cell-based assay for inhibiting HIV-1 replication and promising activities against selected NNRTI-resistant mutants such as Y181L, Y181C, K103N, and L100I were observed.
Sulfanyltriazoles IIIa and IIIc (Figure 1) exhibited EC50 values of 182 and 24 nM, respectively, suggesting the potential of these sulfanyltriazoles to overcome the K103-related NNRTI-resistant mutants. These sulfanyltriazoles could serve as advanced lead structures promising great potential in overcoming these and other NNRTI-resistant mutants [7].
1,2,4-triazoles are a very important class of compounds which attracted the attention of many chemists and biologists in organic synthesis and medicinal and pharmaceutical fields due to their various biological activities such as anticancer [8,9], antimicrobial, anticonvulsant [10], anti-inflammatory [11], antitubercular [12], analgesic [13], antibacterial [14], and anti-HIV [15]. In addition, there are chemotherapeutically known drugs containing 1,2,4-triazole moiety, e.g., fluconazole (1) [16], (2-(2,4-difluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol) and itraconazole (2) [17], (4-(4-(4-(4-(((2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)-phenyl)-1-((S)-sec-butyl)-1H-1,2,4-triazol-5(4H)-one), which are used as very effective antifungal drugs. In addition, prothioconazole (3) [18] is commercially available for the treatment of plant-pathogenic fungal infections, alprazolam (4) [18], (8-chloro-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine), is used for treating of anxiety disorders, and anastrozole (5) [19] in addition to letrozole (6) is used for chemotherapeutic anticancer drugs [20] (Figure 2).
Incorporating of thione group either in 3- or 5-position (A and B, Figure 3) has been reported in numerous reports, leading to enhancement of biological activities related to triazole moiety [21]. Besides, the triazolethione system is considered as a cyclic analog of very important components like thiosemicarbazides and thiocarbohydrazides, which are widely spread as a reactive building block in many organic reactions leading to different heterocyclic rings and having effective biological applications. Many heterocyclic compounds are the main constituents of natural products; also, mercapto-1,2,4-triazole nucleus is found in many natural products and pharmaceuticals [22]. Mercapto-1,2,4-triazole also may be derived from natural products by applying some reactions to get the desired compounds [23].
Triazolethione-thiols (Figure 4) have gained considerable importance in medicinal chemistry due to their potential anticancer [24,25], antimicrobial [26], antioxidant, antitumor [27], anti-tuberculosis [28], anticonvulsant [29], fungicidal [30], antiepileptic [31] and anti-inflammatory [32] activities.
1,2,4-triazolethiones have been prepared successfully by various methods. The most common classical method is the dehydrative cyclization of different hydrazinecarbothioamides in presence of basic media using various reagents such as sodium hydroxide [2,25,33], potassium hydroxide [34,35], sodium bicarbonate [36] or acidic ionic liquid [37] followed by neutralization either with acid or base for both cases, in addition to different other techniques including donor–acceptor interactions. Various synthetic routes and biological applications of spiro-1,2,4-triazolethiones were also discussed as main heterocyclic targets easily obtained from different hydrazinecarbothioamides [38,39].
Schiff bases of triazolethiones [40] have played vital roles in organic synthesis and they are obtained from triazolethiones using simple procedures; also, sometimes their structures possess biological and pharmaceutical activities other than triazolethione itself such as anti-inflammatory and anti-oxidant [41], anticancer [42], fungicidal activities [43], antibacterial [44], antiparasitic [45], antidepressant and antimicrobial [46]. Furthermore, many transition metal complexes of 1,2,4-triazolethione Schiff bases and their bioactivities were reported [47,48,49] along with nickel complexes of triazolethiones [50] showing high catalytic activity towards the synthesis of tetrahydrobenzo[b]pyrans [47].
Various reactions of mercapto-triazolethiones [25] were discussed depending on S and N nucleophilic sites and in presence of different reagents and conditions to afford other heterocyclic compounds, e.g., triazolothiadiazines [51,52], imidazothiadiazoles [51,53], bistriazolethione-1,4-dihydropyridines [54] and fused triazolethione pyrimidines [55].

2. Synthesis of 1,2,4-Triazole-3-thiones

Hydrazinolysis of ethyl-substituted benzoates 7ac yielded the carbonylhydrazides 8ac. Nucleophilic addition of carbon disulfide (CS2) to 8ac in basic media [22] gave the hydrazide oxadiazole-2-thiones 9ac. The reaction of oxadiazoles 9ac with hydrazine hydrate in ethanol afforded 4-amino-5-aryl-1,2,4-triazole-3-thiones 10ac (Scheme 1) [22].
Alkaline cyclization of different substituted acylthiocarbohydrazides 12af, obtained from the reactions of acylhydrazides 11a–f with various isothiocyanates, gave the corresponding 4-alkyl-5-substituted-1,2,4-triazole-3-thiones 13af in 70–86% yields (Scheme 2) [23]. Screening of the anticonvulsant activity of the obtained compounds revealed that they are used as useful anticonvulsant drug candidates whose mode of action depends on voltage-gated sodium channels inhibition (VGSC) (Scheme 2) [23].
A series of 1,2,4-triazole-3-thiones 19ad were successfully prepared through stepwise reaction starting from esterification of N-(4-hydroxyphenyl)acetamide (14) with ethyl bromoacetate (15) to give ethyl 2-(4-acetamido-phenoxy)acetate (16) [24]. The acetohydrazide 17 was then obtained through hydrazinolysis of compound 16 with hydrazine hydrate. The corresponding thiosemicarbazides 18ad were synthesized by the reaction of 17 with different isothiocyanates in dry ethanol. Finally, thiosemicarbazide derivatives 18ad were efficiently cyclized in basic media to give the desired 1,2,4-triazole-3-thiones 19ad in 52–88% yields [24] (Scheme 3).
Reactions of thiosemicarbazide (20) with arylidene malononitrile afforded 5-(4-chlorophenyl)-1,2,4-triazolidine-3-thione 22a via the intermediate 21, whereas the reaction of 4-substituted thiosemicarbazides 23a,b with 4-chlorobenzaldehyde gave the corresponding 5-(4-chlorophenyl)-4-substituted-1,2,4-triazolidine-3-thiones 24a,b in 89% and 91% yield, respectively (Scheme 4) [50].
Thiosemicarbazide (20) reacted with 3,4-dichlorobenzyl chloride to give 2-(3,4-dichlorobenzyl)hydrazinecarbothioamide (25) which reacted with formic acid to form 1-(3,4-dichlorobenzyl)-1H-1,2,4-triazole-3-thiol (27) in 82% yield through the formation of intermediate 26 (Scheme 5) [51].
The synthesis of 5-substituted phenyl-1,2,4-triazole-3-thiones 30ac was done in high yields from the refluxing of arylidene derivatives and trimethylsilyl isothiocyanate using sulfamic acid as a catalyst via the intermediates 28ac and 29ac (Scheme 6) [52].
Substituted aryl hydrazides 12bf reacted with CS2 in alcoholic potassium hydroxides and yielded potassium hydrazinecarbodithioate salts 31bf. Refluxing of 31ae with a dilute solution of hydrazine hydrate afforded the expected 4-amino-5-substituted-1,2,4-triazole-3-thiones 32ae (Scheme 7) [29].
The reaction of diethyl 1-substituted-1H-1,2,3-triazole-4,5-dicarboxylates 33ad with hydrazine hydrate yielded diacid hydrazides 34ad. Hydrazinecarbothioamides 35ad were obtained via refluxing of 34ad with phenyl isothiocyanate. Dehydrative ring closure of compounds 35ad under basic condition furnished the formation of bis-1,2,4-triazole-3-thiones 36ad in 80–85% yields. Besides, the reaction of diacid hydrazides 34ad with CS2 in basic solution followed by refluxing with hydrazine hydrate gave bis-4-amino-1,2,4-triazole-3-thiones 37ad in 80–85% yields (Scheme 8) [28]. The resulting compounds were screened for their antimicrobial activities based on standard antimicrobial agents; compound 37d exhibited comparable antibacterial and antifungal activities against all the tested organisms [28].
Thiocarbohydrazide (38) was heated with 2-(thiophen-2-yl)acetic acid to get 4-amino-1,2,4-triazole-3-thione (39). The reaction of 39 with different aryl aldehydes yielded the corresponding Schiff bases 40af in 52–61% yields (Scheme 9) [53]. All the synthesized compounds were screened against Mycobacterium tuberculosis H37Rv, and they proved to be less active than rifampicin (98%), used as reference drug. Compound 40f showed the highest inhibition (87%), and therefore, it was suggested to be as potentially active antituberculosis agent [53].
4-Methyl benzoylisothiocyanate was reacted with phenylhydrazine hydrate afforded 1-phenyl-5-(p-tolyl)-1H-1,2,4-triazole-3(2H)-thione (41). Schiff bases of triazolethione 42aj were obtained via reaction of triazolethione 41 with formaldehyde and various aromatic amines (Scheme 10) [54]. Screening of the synthesized compounds 42aj against different microorganisms showed that they have good antifungal activity rather than antibacterial activity [56].
Diflunisal (2′,4′-difluoro-4-hydroxybiphenyl-3-carboxylic acid) (43) was converted to its corresponding diflunisal ester 44. The desired diflunisal hydrazide 45 was obtained using hydrazine hydrate. The reaction of hydrazide 45 with various aryl isothiocyanates afforded substituted hydrazinecarbothioamides 46af. Cyclization of compounds 46af to the corresponding triazole-3-thiones 47af occurred in basic media (Scheme 11) [57]. The screening of compounds 47af against cancer cells revealed that compound 47f was found to be active against the colon carcinoma HCT-116 cancer cell line with a 6.2 μM IC50 value. In addition, compounds 47e and 47f were found active against the human breast cancer T47D cancer cell line with IC50 values of 43.4 and 27.3 μM, respectively [57].
Pyridine-2,5-dicarbohydrazide (49) was synthesized from the reaction of dimethylpyridine-2,5-dicarboxylic acid (48) with hydrazine hydrate, which reacted with different alkyl/aryl isothiocyanates to afford 2,2′-(pyridine-2,5-dicarbonyl)bis-(N-substituted hydrazinecarbothioamides) 50ae. Ring closure of these hydrazine-carbothioamides 50ae occurred in basic media to give bis-1,2,4-triazole-3-thiones 51ae in 85–95% yields (Scheme 12) [58]. Biological activities of the synthesized compounds 51ae were evaluated, and they showed high antioxidant activity. Moreover, all of the synthesized compounds efficiently inhibited some metabolic enzymes such as AChE (acetylcholinesterase I and II) and could be used as excellent candidate drugs in the treatment of some diseases such as mountain sickness, glaucoma, gastric and duodenal ulcers, epilepsy, osteoporosis, and neurological disorders [58].
Ethyl (2-aroylaryloxy)acetates 53ad were synthesized from hydroxyl-benzophenones 52ad with ethyl chloroacetate. The reaction of 53ad with hydrazine hydrate gave the corresponding acylhydrazides 54ad. Intramolecular cyclization of 54ad with CS2 in alkaline media resulted in oxadiazole-2-(3H)thiones 55ad. 1,2,4-Triazolo-3-thiones 56ad were synthesized from the reaction of compounds 55ad with hydrazine hydrate. In addition, triazolothiadiazines 57ad were synthesized from the reaction of 56ad with phenacyl bromide [50]. The screening of compounds 55ad and 57ad revealed that they possess a higher antibacterial activity than antifungal activity; also, the halo-substituted compounds showed an increased growth inhibition activity higher than that of the reference drugs such as fluconazole and chloramphenicol (Scheme 13) [50].
Chlorosulfonation of ethyl 2-(3,4-dimethoxyphenyl)acetate (58) gave ethyl 2-(2-(chlorosulfonyl)-4,5-dimethoxyphenyl)acetate (59) (Scheme 14). Sulfonamides 60ae were readily obtained via reaction of 59 with secondary amines. The desired acid hydrazides 61ae, which were obtained by reaction of 60ae with hydrazine hydrate, were condensed with various isothiocyanates to yield the corresponding hydrazinecarbothioamides 62ae. Further, 1,2,4-Triazole-3-thiones 63ae were synthesized in 44–75% yields from the cyclization 62ae in basic media (Scheme 14) [47]. Screening of compounds 63ae for in vitro antifungal and antibacterial activity revealed that they have the best antifungal activity compared with the reference bifonazole in addition to the same bactericidal activity as streptomycin, except for Enterobacter cloacae and Salmonella species [47].
Refluxing of thiocarbohydrazide (38) with acetic acid or trifluoroacetic acid gave 4-amino-5-substituted-4H-1,2,4-triazole-3-thiones 11d,e (Scheme 15) [42].
Various thiosemicarbazide derivatives 65ac were then synthesized from the reaction of acid hydrazides 64ac with 3-fluorophenyl isothiocyanates. Further, 1,2,4-triazole-3-thiones 66ac were obtained from alkaline cyclization of compounds 65ac with 8% NaOH solution (Scheme 16) [40].
Treatment of oxadiazole thione 10a with hydrazine hydrate gave 4-amino-triazolethione (11a) which on reacting with various aldehydes gave the Schiff bases of triazolethiones 67ad. The synthesis of 1,3,4-trisubstituted triazolethiones 69ad was carried out from the reaction of triazolethiones 67ad with (2-(acetoxymethyl)-6-bromotetrahydro-2H-pyran-3,4,5-triyl triacetate (68) in good yields (Scheme 17) [30]. The synthesized compounds were screened for their cytotoxic activity against human malignant cell lines (MCF-7 and Bel-7402). Interestingly, 69c showed more potent cytotoxic activity against MCF-7 cells compared with compound 67c. Compound 69b also was more active than compound 67b against MCF-7 and Bel-7402 cells [30].
A series of Pd complexes containing 1,2,4-triazole-3-thiones 71ad [59] were synthesized from the reaction of different thiosemicarbazones 70ad with diphenylphosphinopropane and K2[PdCl4] (Scheme 18). The reaction produced, as a minor product, compound 72 (Scheme 18) [59]. The in vitro cytotoxicity of 71ad was evaluated against the MCF-7 cell line, with cisplatin as a reference. The complexes 71b and 71c showed significant cytotoxicity against the MCF-7 (human breast cancer) cell line compared with cisplatin [59].
Refluxing of 5-benzofuran-2-yl-1-phenyl-1H-pyrazole-3-carbohydrazides 73ah with different aromatic isothiocyanates afforded the desired hydrazinecarbothioamides 74ah. Ring closure of these compounds 74ah occurred through refluxing with aqueous sodium hydroxide to give the target 1,2,4-triazole-3-thiones 75ah in 78–88% yields. On the other side, when 2-bromoacetophenone was reacted with 75ah, the reaction gave the corresponding benzothioates 76ah in 74–86% yields (Scheme 19) [36]. Biological activity of compounds 74ah and 76ah showed that benzothioate 76a has a good antibacterial activity against all pathogenic bacteria compared with the standard chloramphenicol [36].
It was reported that the Eschenmoser coupling reaction was used as an efficient method to get 82–88% of diazenyl-1,2,4-triazole-5-thiones 79ae via nucleophilic attack of disubstituted hydrazinecarbothioamides 77ae on 2,3,5,6-tetrachloro-1,4-benzoquinone (78, p-CHL) which acted as a mediator [33] (Scheme 20).
The suggested mechanism based on initial CT-complexation formation of 80ae, which losses chlorine molecule accompanies with the addition of another molecule of 77 would give the intermediate 81 (Scheme 21). Elimination of an arylamine equivalent from 81 would give the intermediate 82, which undergoes rearrangement to give 83. The addition of a Ph3P molecule to 83 would give 84. The action of Ph3P and Et3N is to initiate the formation of triazolethione 85 via elimination of Ph3P=S and triethylammonium. Dehydrogenation of 85 by a second molecule of 78 would give the expected final product 79 together with dichlorodihydroxybenzene (86) [33] (Scheme 21).
4-Amino-3-(4-methoxybenzyl)-1H-1,2,4-triazole-5(4H)-thione (88) was synthesized in 75% yield by refluxing of potassium 2-(2-(4-methoxyphenyl)acetyl)-hydrazinecarbodithioate (87) with hydrazine hydrate. Condensation of triazolethione 88 with different substituted aldehydes gave Schiff base derivatives 89ac in 85–86% yields (Scheme 22) [43]. Screening of different Schiff bases 89ac for anti-inflammatory and antioxidant activities showed that 89a and 89c were used as potent anti-inflammatory drugs. In addition, compound 89a was the most active antioxidant drug showing an IC50 value of 7.2 ± 2.7 μg/mL compared with that of the reference ascorbic acid (2.61 ± 0.29 g/mL) [43].
(S)-2-(1-Benzylpyrrolidine-2-carbonyl)-N-butylhydrazinecarbothioamide (91) was prepared from the refluxing of (S)-1-benzylpyrrolidine-2-carbohydrazide (90) with butyl isothiocyanate. In addition, it is used as a building block for heterocyclization and synthesis of the desired (S)-3-(1-benzylpyrrolidin-2-yl)-4-butyl-1H-1,2,4-triazole-5(4H)-thione (92a) in 56% yield (Scheme 23) [36].
Moreover, 4-amino-triazole-5-thiol 94 was obtained from two routes, i.e., from the fusion of substituted propanoic acid (93) with 38 or cyclization of potassium hydrazinecarbodithioate derivative 95 with hydrazine hydrate (Scheme 24) [60].
The reaction of triazolethione 94 with different aldehydes in acidic media afforded (E)-4-(substituted amino)-3-(1-(4-isobutylphenyl)ethyl)-4H-1,2,4-triazole-5-thiones 96af in 44–85% yields [61]. One-pot multicomponent reaction of 96af, formaldehyde and secondary amines afforded 2,4,5-trisubstituted triazolethiones 97af. Screening of the anti-inflammatory activity of the synthesized compounds revealed that Mannich bases (97b and 97e) exhibited the highest anti-inflammatory activity. Besides, the most potent anti-inflammatory molecules 97b,df were further examined for their analgesic activity in mice showing better analgesic activity compared to diclofenac [61].
Thiocarbohyrazide (38) was used efficiently as precursor of 4-amino-3-(1,2,3,4,5,6-hexahydroxyhexyl)-1H-1,2,4-triazole-5(4H)-thione (99) through refluxing with D-glucoheptonic acid-1,4-lactone (98) [62]. Besides, the triazole-thione 99 was reacted with different substituted benzaldehydes to afford (E)-4-amino-3-(1,2,3,4,5,6-hexahydroxyhexyl)-1H-1,2,4-triazole-5(4H)-thiones 100af in good to moderate yields (50–70%). Introducing a glycosyl unit into triazolethiones Schiff bases 100af led to good water-solubility of these compounds and also improved their biological activities (Scheme 25) [62].
4-(Hydrazinylcarbonyl)-5-methyl-4,5-dihydro-1H-imidazole-3-oxides 101ai reacted with different isothiocyanates (phenyl, t-butyl, and methyl) to give the corresponding hydrazinecarbothioamides 102ai. Triazole-5-thiones 103ai were obtained in 50–82% yields from the cyclization of substituted imidazole (carbonyl)hydrazinecarbothioamides 102ai in basic media (Scheme 26) [63].
The reaction of different carboxylic acids with thiocarbohydrazide 38 gave aminotriazolethiones 11d,fj in 51–57% yields. In a different manner, the reaction of 38 with ethyl esters of γ-keto acids did not give the expected triazolethiones 104a,b but it gave 6-substituted phenyl-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazine-3(2H)-thiones 105a,b in 35% and 39% yields. The reaction occurred via ring closure of triazole and intramolecular imine condensation of 104a,b (Scheme 27) [64]. The prepared compounds were tested for their inhibitory activities against Mycobacterium bovis BCG; compound 11d proved to be the most potent one against it, with MIC value of 31.25 μg/mL [64].
Natural products are used as staring materials for the synthesis of different mercapto triazoles. Hydrolysis by aqueous KOH of ((2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)penta-2,4-dien-1-one) (106) gave 5-(benzo[d][1,3]dioxol-5-yl)penta-2,4-dienoic acid (107). (5-(Benzo[d][1,3]dioxol-5-yl)penta-2,4-dienehydrazide (108) was obtained after reacting the acid (107) with oxalyl chloride followed by hydrazine hydrate. Compounds 109an were prepared from reaction of the acid hydrazide 108 using different isothiocyanates. Basic hydrolysis of 109an efficiently gave the desired 3-((1E,3E)-4-(benzo[d][1,3]dioxol-5-yl)buta-1,3-dien-1-yl)-4-substituted-1H-1,2,4-triazole-5(4H)- thiones 110an in 32–51% yields (Scheme 28) [18]. The best trypanocidal activity was noted in case of 110g on proliferative forms of Trypanosoma cruzi [18].
Reaction of 2-(coumarin-4-yl)acetic acid with thiocarbohydrazide (38) in refluxing phosphoryl chloride yielded the target 4-((4-amino-5-thioxo-4,5-dihydro-1H-1,2,4-triazole-3-yl)methyl)-2H-chromen-2-one (111) in 80% yield. Condensation of 111 with various aromatic aldehydes yielded (E)-4-((4-(benzylideneamino)-5-thioxo-4,5-dihydro-1H-1,2,4-triazole-3-yl)methyl)-2H-chromen-2-ones 112ac (Scheme 29) [37]. The synthesized compounds were evaluated in vitro as anticancer agents in the human colon cancer (HCT 116) cell line. Compound 112c showed high anticancer activity (relative potency >50%) with IC50 value of 4.363 μM compared to the potent anticancer drug doxorubicin, whereas compound 112a displayed moderate anticancer activity with IC50 values 18.76 μM. The molecular docking studies of the active compounds revealed that these compounds might act via inhibition of tyrosine kinases (CDK2) [37].
Compound 2-(ethylthio)benzohydrazide (114) was obtained by refluxing ethyl 2-(ethylthio)benzoate (113) with hydrazine hydrate. Then, subjecting 114 with various aryl isothiocyanates yielded the thiosemicarbazides 115ae. Compounds 115ae were then cyclized to N-substituted triazolethiones 116ae in 69–75% yields (Scheme 30) [65]. Compounds 115a,b and 116a, were effectively used as antioxidant agents with IC50 values of 1.08, 0.74, and 0.22 μg/mL, respectively, compared to gallic acid (IC50 = 1.2 μg/mL) [65].
Phosphorylated triazolethione 119 was formed in 90% yield from the cyclization process of N-allyl-2-(2-(diphenylphosphoryl)acetyl)hydrazinecarbothioamide 118 (obtained from 2-(diphenylphosphoryl)acetohydrazide (117) with allyl isothiocyanate) in basic media (5%) NaOH [42]. Moreover, ethyl 2-((4-allyl-5-((diphenylphosphoryl)-methyl)-4H-1,2,4-triazole-3-yl)thio)acetate (120) was synthesized in 68% yield by reacting 119 with ethyl bromoacetate. Hydrazinolysis of compound 120 gave 2-((4-allyl-5-((diphenylphosphoryl)methyl)-4H-1,2,4-triazole-3-yl)thio)acetohydrazide (121) in 43% yield (Scheme 31) [42].
Incorporating of triazolethiones into thiazole ring was the optimum pharmacophore model for anticonvulsant activities, thus condensation of ethyl thiazol-2-ylcarbamates 122ad with 4-substituted thiosemicarbazides 23cf afforded the corresponding hydrazinecarbothioamides 123ad. Cyclization of the latter with aqueous sodium hydroxide gave 4-substituted phenyl-3-((4-aryl-4,5-dihydrothiazol-2-yl)amino)-1H-1,2,4-triazole-5(4H)-thiones 124ad in 62–84% yields [66] (Scheme 32). The obtained compounds were screened for their anticonvulsant activity and showed that compounds 124d and 124e had a significant anticonvulsant activity compared with the standard drugs [66].
The condensation of (E)-1-(phenoxathiin-2-yl)-3-phenylprop-2-en-1-one (125) with malononitrile afforded 2-amino-6-(phenoxathiin-2-yl)-4-phenylnicotinonitrile (126). In addition, compound 126 reacted with triethyl orthoformate in acetic anhydride to give formimide 127, which upon hydrazinolysis with phenyl hydrazine yielded 4-imino-7-(phenoxathiin-2-yl)-5-phenylpyrido[2-d]pyrimidin-3(4H)-amine (128). The reaction of the latter with CS2 gave 16-phenyl-[1,2,4]triazolo-pyrimido[4-b]benzo[5,6][1,4]oxathiino[3,2-g]quinoline-2(3H)-thiones 129 (Scheme 33) [50].
2-(Adamantanyl-1-carbonyl)-N-phenylhydrazinecarbothioamide (130) was synthesized from the reaction of adamantane-1-carbohydrazide (9d) with phenyl isothiocyanate. Thereafter, 3-(adamantan-1-yl)-4-phenyl-1H-1,2,4-triazole-5(4H)-thione 131a was synthesized via basic hydrolysis of 130a with NaOH. Then, 3-(adamantan-1-yl)-1-((piperidin-4-yl)methyl)-4-phenyl-1H-1,2,4-triazole-5(4H)-thiones 132af were obtained from the reaction of compound 131a with 1-substituted piperazine and formaldehyde solution [34] (Scheme 34). The synthesized N-Mannich bases of triazolethiones 132bf screened against Gram-positive and -negative bacteria in addition to some pathogenic fungus (Candida albicans) revealed that they had potent antibacterial activity [34].
Hydrolysis of disubstituted hydrazinecarbothioamides 130bd with aqueous sodium hydroxide gave 1,2,4-triazole-5-thiones 92bd. Mannich reaction of 1,2,4-triazole-5-thiones 92bd, 1-[(1R,2S)-2-fluorocyclopropyl]CPFX (133) and formaldehyde afforded 1-[(1R,2S)-2-fluorocyclopropyl]CPFX-1,2,4-triazole-5-thiones 134ac in 52–57% yields (Scheme 35) [67].
Antibacterial activity against different pathogens showed that all of the CPFX-1,2,4-triazole-5-thiones 134ac were more potent than the parent 1-[(1R,2S)-2-fluorocyclopropyl]-CPFX 133 and comparable to ciprofloxacin and levofloxacin against the majority of the tested pathogens. Moreover, the anti-Gram negative bacterial activity of 134ac was far more potent than the reference named Vancomycin (VAN) [67].
The reaction of acid hydrazide 9eg and 2-(4-isothiocyanatophenyl)-1H-benzo[d]imidazole gave N-(4-(1H-benzimidazol-2-yl)phenyl)-2-benzoylhydrazine-carbothioamides 135. Ring closure of compound 135 in acidic media afforded 1,2,4-triazole-5-thiones 136 [28] in 55–64% yields (Scheme 36). Screening of the obtained compounds for antibacterial and antifungal activities showed that some of these compounds exhibited good antibacterial and antifungal activities [28].
Condensation of 4-amino-3-methyl-1-phenyl-1H-thieno[2,3-c]pyrazole-5-carbonitrile (137) with triethyl orthoformate in the presence of acetic anhydride as catalyst gave (Z)-ethyl N-(5-cyano-3-methyl-1-phenyl-1H-thieno[2,3-c]pyrazol-4-yl)formimidate (138). Hydrazinolysis of 138 with hydrazine hydrate yielded 7-imino-3-methyl-1-phenyl-1H-pyrazolothieno[3,2-d]pyrimidin-6(7H)-amine (139), whereas cyclization of pyrazolothienopyrimidines 139 with CS2 afforded 7-methyl-9-phenyl-3,9-dihydro-2H-pyrazolothieno[2,3-e][1,2,4]triazolo[1,5-c]pyrimidine-2-thione (140) in 35% yield (Scheme 37) [54].
The cyclization reaction of longer alkenyl/hydroxyl alkenyl acid hydrazides 9hk CS2/KOH followed by treatment with hydrazine hydrate yielded the corresponding 4-amino-3-substituted-1H-1,2,4-triazole-5(4H)-thiones 11kn. 1,2,4-Triazolothiadiazines 141ad were directly obtained from the reaction of amino triazolethiones 11kn with phenacyl bromide in 62–90% yields (Scheme 38). In vitro screening of anticancer activity against three different cell lines, i.e., human hepatocellular carcinoma (Hep3B), human breast adenocarcinoma (MCF7), and human cervical carcinoma (HeLa), towards triazolethione and triazolothiadiazines showed that the nature of the long-chain on third position affected the potency of these drugs. Besides, fused triazolothiadiazines 141ad were found to be potential anticancer agents [68].
Similarly, the reaction of acid hydrazides 142ai with isothiocyanates afforded the acylhydrazides 143ai (Scheme 39). The triazolethiones 144ai were then obtained in 62–90% yields from the reaction of thiosemicarbazides 143ai in NaHCO3 in ethanol (Scheme 39) [69]. The 1,2,4-triazolethione 144g was found to be the best anti-inflammatory nucleus via inhibiting both COX-2 (IC50 = 2.1 μM) and 5-LOX (IC50 = 2.6 μM) enzymes, and this was supported via enzyme-ligand molecular modeling (docking studies), which gave favorable binding interactions in both COX-2 and 5-LOX active sites. It also has a superior gastrointestinal safety profile (ulcer index = 0.25) compared to the reference drug [69].
Interestingly, esterification of 1H-benzimidazoles 145ae with ethyl chloroacetate gave ethyl 2-(2-phenyl-1H-benzo[d]imidazol-1-yl)acetates 146ae, which upon reacting with hydrazine hydrate gave the acid hydrazide 147ae. Also, N-methyl-2-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)acetyl)hydrazinecarbothioamides 148ae were formed by the reaction 147ae with methyl isothiocyanate. Ring closure of hydrazine-carbothioamides 148ae with aqueous NaOH afforded the biologically active triazolethiones 149ae in 51–64% yields, with significant antioxidant properties (Scheme 40) [70].
Reaction of 2-((3,5,6-trichloropyridin-2-yl)oxy)acetic acid (150) with thionyl chloride gave compound 151. Additionally, the treatment of compound 151 with hydrazine hydrate gave (3,5,6-trichloropyridin-2-yl)hydrazine-carboxylate (152). When the acid hydrazide 152 was then subjected to aqueous potassium thiocyanate, 2-(2-((3,5,6-trichloropyridin-2-yl)oxy)acetyl)hydrazine-carbothioamide (153) was obtained. Cyclization of 153 in basic media afforded 1H-1,2,4-triazole-5(4H)-thione 154) [71]. On the other side, various S-alkylated products 155ae were obtained via reacting substituted benzyl chlorides with triazolethiones 154. However, the reaction of morpholine, formaldehyde, and compound 155ae gave the N-alkylated morpholino-triazolethiones 156ae, which on oxidation with H2O2 in acidic media gave 3,4,5-trisubstituted-1,2,4-triazoles 157ae in 54–69% yields [71]. The synthesized compounds 157ae screened for their antimicrobial activity revealed that 157c exhibited better antibacterial and antifungal activities than the other compounds (Scheme 41) [71].
On refluxing of 1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazole-4-carbaldehyde (158) with thiosemicarbazide (20), the reaction proceeded to give the corresponding 3-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-1H-1,2,4-triazole-5(4H)-thione (159) (Scheme 42). The bioassay of triazolethione 159 showed that it has significant anti-inflammatory activity [72].
Fusion of thiocarbohydrazide (38) with 2-(1,3-dioxoisoindolin-2-yl)acetic acid (160) gave the 2-((4-amino-5-thioxo-4,5-dihydro-1H-1,2,4-triazole-3-yl)methyl)-isoindoline-1,3-dione (161) in 69% yield. The synthesis of triazolethione Schiff bases 162ai was achieved, in 35–66% yield, by refluxing of 161 with different aromatic aldehydes. Besides, Mannich bases 163ah were easily obtained from the reaction of Schiff bases 162ai with formaldehyde and morpholine in 39–82% yields (Scheme 43) [73]. The antimicrobial bioassay of these compounds 163ah showed that antimicrobial activity was increased by introducing azomethine group and also by the addition of morpholine group leading to prospective antimicrobial agents with 163ab, 163ef, and 163h [73].

Synthesis of Spiro-1,2,4-triazolethiones

Spiro-triazolethiones 165ac were also obtained from donor–acceptor interactions in such as in case of reacting hydrazinecarbothioamides 23a,gh with trinitrofluorenone (DTF) 164 in addition to 1,4-disubstituted hydrazine-carbothioamides 166ac in 23–25% yields, respectively (Scheme 44) [74].
It was reported that thiosemicarbazide (20) reacted with dihydropyridazin-1(4H)-yl)acetate to get ethyl 2-(substituted phenyl)-3-thioxo-1,2,4,6,7-pentaazaspiroacetate (168) [75] (Scheme 45).
Patil et al. [32] reported the synthesis of a series of spiro-1,2,4-triazole-3-thiones 169ag varied from good to excellent yields (55–95%) from thiosemicarbazide (20) and different cyclic ketones using different catalysts, the most effective catalyst was 1,1′-sulfinyldipyridinium bis(hydrogen sulfate) ionic liquid which gave high yield and short reaction time in alcohol at room temperature (Scheme 46).
The synthesis of 1-acetyl-5′-thioxospiro[indoline-3,3′-[1,2,4]triazolidin]-2-one (170), in 87% yield, was achieved by the reaction of 1-acetylindoline-2,3-dione with thiosemicarbazide 20 catalyzed by acidic ionic liquid (Scheme 47). Compound 170 showed good antibacterial activity [30].
Reactions of thiosemicarbazides 171aj with various π-acceptors such as benzo- or naphthoquinones 78a,b led to different fused heterocyclic rings [76]. However, spiro-1,2,4-triazole-3-thiones 174aj were obtained from the reaction of cycloalkanone-thiosemicarbazides 171aj with benzo- or naphthoquinones 78a,b in 80–85% yields (Scheme 48) [76].
Substituted thiosemicarbazone 176 was cyclized to the corresponding spirotriazolethione 179 in 70–82% yields through the intermediates 177 and 178 (Scheme 49) [77].
(1R,2R,4R,5S)-2,4-Disubstituted phenyl-3-azabicyclo[3.3.1]nonan-9-one hydro-chlorides 180ag reacted with ammonia to give (1R,2R,4R,5S)-2,4-disubstituted phenyl-3-azabicyclo[3.3.1]nonan-9-ones 181ag (Scheme 50) [31]. Condensation of compounds 181ag with thiosemicarbazide 20 afforded compounds 182ag, which upon cyclization in the presence of m-chlorobenzaldehyde efficiently gave spiro-1,2,4-triazoline-3′-thiones 183ag in 50–70% yields (Scheme 50). Screening of these spiro-triazolethiones 183ag for antibacterial and antifungal activities showed that compounds 183be had excellent antifungal activity against all the tested microorganisms. However, compounds 183d,e showed excellent antibacterial activity against β-H. streptococcus. Besides, compounds 183bc,e showed varied activities toward the tested Gram-positive and -negative strains [31].
5-Substituted-5′-thioxospiro[indoline-3,3′-[1,2,4]triazolidin]-2-ones 185ad (83–89% yields) successfully were obtained from the reaction of different 5-substituted indoline-2,3-diones 184ad with 20 in water and catalyzed by using glycine nitrate. In the same manner, bis-spirotriazolethione 187 was synthesized from the reaction of 1,1′-(propane-1,3-diyl)bis(5-bromoindoline-2,3-dione) 186 with 20 in 89% yield (Scheme 51) [78].
Condensation of gonanone derivatives 188ac with 20 in acidic media gave the corresponding thiosemicarbazones 189ac. Oxidative cyclization of thiosemicarbazones 189ac with hydrogen peroxide yielded the corresponding (5S)-10,13-dimethyl-17-octylhexadecahydrospiro-[cyclopenta[a]phenanthrene-6,3′-1,2,4triazolidine]-5′-thiones 190ac in 66–78% yields (Scheme 52) [79].
Microwave irradiation was used as an efficient method to get good yields with a shorter time than the classical method for the synthesis of 6,6-dimethyl-phenyl-1,2,4,8-tetrazaspiro[4.5]decane-3-thiones 193ae via formation of thiosemicarbazone intermediates 192ae, which was obtained from the reaction of 3,3-dimethyl-phenylpiperidin-4-ones 191ae with 20 (Scheme 53) [80].
Similarly, the reaction of 3-alkyl-2,6-diphenylpyran-4-ones 194af with 20 or 4-phenyl hydrazinecarbothioamides 23 gave thiosemicarbazones 195af. Oxidative cyclization of 195af with hydrogen peroxide led to the expected 7,9-diphenyl-8-oxa-1,2,4-triazaspiro[4.5]decane-3-thiones 196af. The synthesized compounds were tested for antimicrobial activity against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Salmonella typhi, Aspergillus flavus, Aspergillus niger, Candida albicans, and Rhizopus sp. Compounds 196e and 196f showed potent antibacterial activity against E. coli and S. typhi. However, compounds 196d and 196f were potent against Rhizopus sp., whereas compound 196e gave significant antifungal activity against Aspergillus flavus (Scheme 54) [81].
Aly et al. [82] reported that reaction of equal equivalents of both N-substituted hydrazinecarbothioamides 23a,i with 2-(bis(methylthio)methylene)malononitrile (197) in dry ethanol catalyzed by few drops of Et3N for 3 h afforded a colorless precipitate of 5-amino-4-cyano-3-(methylthio)-N-phenyl-1H-pyrazole-1-carbothioamide (198) as the major product in 65% yield together with 3,4-disubstituted amino-1H-1,2,4-triazole-5(4H)-thiones 199a,b and pyrazole carbonitrile 200 as minor products (Scheme 55) [82].

3. Reactions of 1,2,4-Triazolethiones

3.1. Synthesis of Open-Chain Compounds

The synthesis of mono and bipolar surfactants 201ad and 202ad was achieved by the reaction of 3-methyl-1H-1,2,4-triazole-5(4H)-thione (30c) and 3-phenyl-1H-1,2,4-triazole-5(4H)-thione (30d) with various alkyl bromides. However, in the case of n-dodecyl bromide, a mixture of two isomers 203 and 204 was obtained from the reaction of 201ad and 202ad with another molecule of alkyl bromide. In addition, bis-1,2,4-triazoles 205a,b were obtained from the reaction of linear dibromoalkanes with 3-methyl-1H-1,2,4-triazole-5(4H)-thione (30c) (Scheme 56) [83].
Actylation of 3-substituted aminotriazolethione 206 by acetic anhydride afforded 4-substituted-1,2,4-triazole-5-thione 207 in 52% yield (Scheme 57). Additionally, ethyl 2-((4-amino-5-((6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyridin-3-yl)methyl)-4H-1,2,4-triazole-3-yl) thio)acetate (208) can be obtained in 50% yield upon reacting ethyl 2-bromoacetate with compound 206 (Scheme 57) [84].
Reaction of various 1,2,4-triazolethiones 19ag with alkyl or aryl isothiocyanates gave 1-substituted-3-(4-((4-substituted-5-thioxo-4,5-dihydro-1H-1,2,4-triazole-3-yl)-methoxy)phenyl)thio-ureas 209ag (Scheme 58). All the synthesized compounds 209ag evaluated against antiviral, anti-HIV, and anti-tuberculosis activity showed that compound 209g was the most active one with 79% inhibition against Mycobacterium tuberculosis H37Rv and also gave moderate protection against Coxsackievirus B4 with an MIC value of 16 mg/mL and a selectivity index of 5 [21].
Condensation of 4-amino-5-(pyridin-3-yl)-1,2,4-triazolidine-3-thione (11o) with 4-chlorobenzaldehyde yielded 4-chlorobenzylideneamino-5-(pyridin-3-yl)-1,2,4-triazolidine-3-thione (210). (E)-4-Chloro-benzylideneamino-5-(methylthio)-3-(pyridin-3-yl)-1,2,4-triazole 211 was synthesized form the reaction of 210 with methyl iodide. Finally, the trisubstituted 1,2,4-triazole 215 was synthesized in presence of iodide anion through the intermediates 212214 (Scheme 59) [85].
The reaction of propargyl bromide with 5-(substituted phenyl)-1,2,4-triazolidine-3-thiones 21a,cj yielded 3-substituted-5-(prop-2-yn-1-ylthio)-4,5-dihydro-1H-1,2,4-triazoles 216ai in 62–77% yields. Besides, the reaction of compounds 216ai with iodine afforded (E)-5-((2,3-diiodoallyl)thio)-3-(substituted phenyl)-1,2,4-triazoles 217ai in 75–92% yields and traces of thiazolotriazoles 218ai in 44–59% yields (Scheme 60) [86].
The synthesis of S- and N-alkylated products of triazolethiones 219 and 220 was achieved by the reaction of 1-(3,4-dichlorobenzyl)-1H-1,2,4-triazole-3-thiol (27) with 1-bromooctane in basic media using tetrabutylammonium bromide (TBAB) as a catalyst in acetone for several minutes. Besides, 3-((2-bromoethyl)thio)-1-(3,4-dichlorobenzyl)-1H-1,2,4-triazole (221) and 2-(2-bromoethyl)-1-(3,4-dichlorobenzyl)-1H-1,2,4-triazole-3(2H)-thione (222) were prepared from the reaction of 27 with 1,2-dibromoethane as mentioned before. On the other hand, reacting 222 with 1,2,4-triazole afforded 2-(2-(1H-1,2,4-triazol-1-yl)ethyl)-1-(3,4-dichlorobenzyl)-1H-1,2,4-triazole-3(2H)-thione (223), whereas reaction of 1,2,4-triazole with 221 gave 3-((2-(1H-1,2,4-triazol-1-yl)ethyl)thio)-1-(3,4-dichlorobenzyl)-1H-1,2,4-triazole (224) [87]. The screening of antibacterial and antifungal activities showed that introducing a triazolium moiety in 223 and 224 would improve antibacterial and antifungal activities [87] (Scheme 61).
Reaction of 4-phenyl-5-(pyridin-3-yl)-1,2,4-triazole-3-thiol (92b) with ethyl bromoacetate gave 1,2,4-triazolthioacetate 225 which on reacting with hydrazine hydrate afforded the desired acetohydrazide 226. Moreover, the synthesis of various N-substituted-2-(2-((4-phenyl-5-(pyridin-3-yl)-4H-1,2,4-triazole-3-yl)thio)acetyl)hydrazinecarbothioamides 227af was achieved by reacting 226 with isothiocyanates (Scheme 62) [88].
Subjecting 4-substituted 3-((diphenylphosphoryl)methyl)-1H-1,2,4-triazole-5(4H)-thiones 119a,b with ethyl acrylate gave ethyl 3-(3-((diphenylphosphoryl)methyl)-4-substituted-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)propanoates 228ac [89] (Scheme 63).
The Schiff bases of 4-amino-3-((phenoxy)methyl)-1H-1,2,4-triazole-5(4H)-thiones 230ae were synthesized upon reacting 4-aminotriazolethiones 229ae with different aldehydes. Additionally, reaction of 230ae with chloroacetic acid and catalyzation by pyridine gave 2-((4-(substituted benzylideneamino)phenoxymethyl-4H-1,2,4-triazole-3-yl)thio)acetic acid derivatives 231ae in 66–70% yields. The former compounds were screened for antimicrobial activities showing that compounds 231b and 231d have good antifungal activities against Aspergillus niger, Cryptococcus neoformans, and Aspergillus fumigatus at MIC of 0.25 μg/mL compared to the standard drug fluconazole with MIC of 1 μg/mL (Scheme 64) [90].
The reaction of 11o with compound 68 afforded disubstituted aminotriazolethiones 232 in 57% and 233 in 40%. Deamination of compounds 232 and 233 was achieved using nitrous acid in acidic media to afford 234 and 235 in 75% and 85% yield, respectively. In addition, deacetylation of 234 and 235 with methanolic ammonia gave the free nucleosides 236 and 237 in 70% and 88% yield, respectively [91]. Screening of antibacterial and antifungal activities of these compounds revealed that S-alkylated derivatives 232, 234, and 236 have a higher inhibitory effect against Aspergillus fumigatus, Syncephalastrum racemosum, and Staphylococcus aureus as well as a lower inhibitory effect against Penicillium italicum and Bacillus subtilis compared to N-alkylated derivatives 233, 235, and 237 (Scheme 65) [91].
Refluxing of 3-(adamantan-1-yl)-4-methyl-triazolethione 131b with 2-aminochloride derivatives afforded S-(2-aminomethyl) and N-(2-aminomethyl) derivatives 238 and 132g in 3:1 ratio, respectively [92]. Besides, 3-(adamantyl)-5-((2-methoxyethyl)thio)-4-phenyl-1,2,4-triazole 239 was obtained from the reaction of 1-bromo-2-methoxyethanone with 3-(adamantan-1-yl)-4-phenyl-1H-1,2,4-triazole-5(4H)-thione 131a. However, in the case of ethyl bromo acetate, two products were formed, ethyl 2-((5-(adamantan-1-yl)-4-phenyl-1,2,4-triazole-3-yl)thio)acetate 240 that converted to 2-((5-(adamantan-1-yl)-4-phenyl-4H-1,2,4-triazole-3-yl)thio)acetic acid 241. Moreover, reaction of aryl methyl halides with 3-(adamantan-1-yl)-4-phenyl-1H-1,2,4-triazole-5(4H)-thione 131a afforded 3-(adamantan-1-yl)-5-((substituted benzyl)thio)-4-phenyl-4H-1,2,4-triazoles 242ae (Scheme 66). The synthesized compounds were tested against anti-inflammatory and antimicrobial activities. Compounds 240 and 241 exhibited good anti-inflammatory activity, whereas compounds 240, 241, and 242ce proved potent antibacterial activity against the tested microorganisms (Scheme 66) [92].
The reaction of aminotriazolethiones 243ai with different aldehydes afforded various arylidenes 244al, which upon reacting with 133 gave substituted triazoles 245ai (Scheme 67). The bioassay of antibacterial and antifungal activities of 245ai revealed that they have better antifungal than antibacterial activities; also, compounds 245b,c,f,j,k,l showed excellent antifungal activity against Candida albicans with an MIC of 16 μg/mL [93].
Mannich reaction of arylidene derivatives of triazolethiols 246 with formaldehyde and benzyl piperazine or 4-substituted pyrimidyl/phenyl/pyridylpiperazine in ethanol at room temperature led to new Mannich bases 247ac and 248ac in 67–74% and 72–83% yields, respectively [94] (Scheme 68). The bioassay of the synthesized compounds revealed that these compounds could be used as new fungicides, whereas compounds 247ac exhibited higher and wider fungicidal activities comparable with that of control triadimefon (Scheme 68) [94].
Reacting 4,5-disubstituted triazolethiones 249 with pipemidic acid 250 afforded 8-ethyl-2-(4-((3,4-disubstituted-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)methyl)piperazin-1-yl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives 251, which exhibited significant antimicrobial activities [95] (Scheme 69).
Schiff bases of triazolethiones 67ac were obtained from the reaction of 4-substituted benzaldehyde with 4-amino-3-substituted-1,2,4-triazole-5-thiones 11ac. Besides, the reaction of compounds 67ac, formaldehyde, and 4-substituted piperazine gave the corresponding Mannich base 252ac. In addition, bis-Mannich base derivatives 253ac were synthesized in case of reaction of 67ac with piperazine (Scheme 70) [52].
Reaction of 3,4-disubstituted triazolethioles 66ac with 2-bromoacetophenones gave ((3,4-disubstituted-1,2,4-triazole-3-yl)thio)-1-phenyl-ethanones 254ac in 70–82% yields and ((3,4-disubstituted-1,2,4-triazole-3-yl)thio)-1-(4-fluorophenyl)ethanones 255ac in 72–85% yields [96]. The screening of the antioxidant activity using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) method revealed that the corresponding hydrazinecarbothioamides showed excellent antioxidant activity, while 1,2,4-triazole-3-thiones showed good antioxidant activity (Scheme 71) [96].
The reaction of 4-amino-5-((4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)methyl)-4H-1,2,4-triazole-3-thiol (256) with benzyl bromide gave 3-(benzylthio)-5-((4-(bis(4-fluorophenyl)-methyl)piperazin-1-yl)methyl)-4H-1,2,4-triazole-4-amine (257) in 72% yield (Scheme 72) [97].

3.2. Synthesis of Substituted Triazolethiones

Synthesis of Pyrazolo-1,2,4-triazoles

Compounds 4-Amino-5-(3-substituted pyrazolyl)triazolethiols 259ad, 260a,b, and 261ac in 61–78% yields were synthesized via reacting 4-aminotriazole-3-thiol (258), dimethoxy-N,N-dimethylmethanamine, and carbonyl compounds using acidic media (orthophosphoric acid) as catalyst [98] (Scheme 73). The mechanism describing the role of orthophosphoric acid is presented in Scheme 74.
Condensation of 5-chloro-1-phenyl-3-(substituted)-1H-pyrazole-4-carbaldehyde with amino-triazolethiones 11d,e furnished the corresponding Schiff bases 246a,b. Bis-aminotriazolethiones 262a,b can be obtained effectively in high yields (83–89% yields upon reaction of 246a,b with piperazine and formaldehyde in ethanol at room temperature) (Scheme 75) [61].

3.3. Synthesis of Fused Triazoles

3.3.1. Synthesis of Fused Pyrazolotriazoles

The synthesis of pyrazolotriazoles 265ad was easily established in 75–80% yields from the reaction of 4-amino-5-(substituted indole)-1,2,4-triazole-3-thiols 263ad with N-arylhydrazonoacetates using basic media of triethylamine via the intermediate 264ad. Desulfurization and ring contraction of compounds 264ad gave the target compound 265ad (Scheme 76) [99].

3.3.2. Synthesis of Thiazolotriazoles

The condensation reaction of 3-substituted-1,2,4-triazole 266ac with chloroacetic acid in acidic media afforded thiazolotriazoles 267ac in 65–69% yields. Interestingly, the synthesized compounds were screened for their antioxidant and antimicrobial activities [100] (Scheme 77). Compound 267a exhibited effective antimicrobial activity towards all the tested organisms.
However, in case of refluxing of 4H-1,2,4-triazole-3-thiol (268) with chloroacetic acid and different aldehydes or isatin derivatives in acidic media, various 5-substituted arylidene-thiazolotriazoles 269ae in 49–68% yields or (Z)-5-(1-acetyl-2-oxo-1H-indol-3(2H,3aH,7aH)-ylidene)thiazolo[3,2-b]-1,2,4-triazol-6(5H)-ones 270 were efficiently synthesized in 40% yield (Scheme 78) [101]. Screening of the obtained compounds for anticancer activity revealed that 5-arylidene-[1,3]thiazolo[3,2-b][1,2,4]triazol-6-ones 269ae exhibited more potent anticancer activity than respective amides [101].
The reaction of different bromomalononitrile derivatives with 3-substituted triazolethiones 30ae produced the corresponding thiazolo-1,2,4-triazole carbonitriles 271ae [102] (Scheme 79).
The synthesis of N-aryl-2-(6-oxo-5,6-dihydrothiazolo[3,2-b][1,2,4]triazol-5-yl)acetamides 272 was achieved in 60–87% yields from the reaction of 268 with N-arylmaleimides in acidic media. It was established from the structure–activity relationship of these compounds that halo-substituted derivatives have a considerable increase in anticancer activities [103] (Scheme 80).
Shah et al. [104]. have reported the synthesis of thiazolotriazoles 275 in 77–85% yields via refluxing of 5-phenyl-1,2,4-triazole-3-thiol (30d) with dibenzoylacetylene (273) through the intermediate 270 (Scheme 81).

3.3.3. Synthesis of Triazolothiadiazoles

Triazolo[3,4-b][1,3,4]thiadiazoles 276ag and 277ae were obtained from refluxing of different aromatic carboxylic acids with 11o in the presence of phosphorous oxychloride [105]. Screening of the synthesized compounds against lung carcinoma (H157) and kidney fibroblast cell lines (BHK-21) showed that compound 277d has the highest inhibition activity of 74.0% for BHK-21 cells which is the same as that of standard drug vincristine (74.5%). Compound 276c,d,g showed less inhibition values, and triazolothidiazole 276a was the most potent compound with inhibition value of 85.5%, whereas compounds 276b,f and 277a exhibited less inhibition values (Scheme 82) [105].
The synthesis of fused heterocyclic[1,2,4]triazolo[3,4-b]-1,3,4-thiadiazoles 278ac and 281ac was done by the reaction of 4-amino-5-(4-((4-X-phenyl)sulfonyl)phenyl)-4H-1,2,4-triazole-3-thiol (11p,q) with aryl isothiocyanates or with various aromatic acids. Antimicrobial screening of the synthesized compounds showed that they had good antimicrobial activity (Scheme 83) [106].
When 3-substituted methylaminotriazolethione 11r was condensed with different aldehydes, arylidene derivatives of triazolethiones 282ac were obtained in 54–66% yield, whereas triazolothiadiazoles 283ac, in 48–74% yields, were synthesized from the reaction of compound 282ac with iodine. In addition, 6-mercapto-1,2,4-triazolothiadiazoles 284 were synthesized upon reaction of 11r with CS2 in pyridine. The synthesis of 4-((6-(ethylthio)-[1,2,4]triazolo[3,4-b][1,3,4]-thiadiazol-3-yl)methyl)-2H-chromen-2-one 285 was occurred from reaction of 11r with methyl iodide in basic media in 55–75% yields. Moreover, 6-methylthio derivative 285 reacted with different aromatic amines to give triazolothiadiazoles 286ac (in 55–75% yields). The obtained compounds were evaluated in vitro as anticancer agents in the human colon cancer (HCT 116) cell line where the aminosulfanyl derivative 286c exhibited high anticancer activity (Scheme 84) [37].

3.3.4. Synthesis of 1,2,4-Triazolothiazines

The synthesis of triazolothiazines 287ai (in 48–72% yields) was done from the reaction of compound 217ai with CuI and tetramethylethylenediamine (TMEDA) using basic media (Scheme 85) [107].
UV irradiation of disubstituted triazole-5(4H)-thione 288ae under basic conditions gave a mixture of 3-substituted triazolothiazines 289ae and 3,4-disubstituted-1,2,4-triazoles 290ae according to the concentration of the base used. However, irradiation of 288ae in presence of acetophenone and only compounds 290ae was observed [108,109] (Scheme 86).
Reaction of 92c with 2-chlorobenzoylketene 292 afforded 3-methyl-7-oxo-2,6-diphenyl-3,7-dihydro-[1,2,4]triazolo-[5,1-b][1,3]thiazin-8-ium-5-olate 293 in 66% yield [110] (Scheme 87).

3.3.5. Synthesis of 1,2,4-Triazolothiadiazines

Cyclocondensation of 4-amino-3-(4-(methylsulfonyl)benzyl)-1H-1,2,4-triazole-5(4H)-thione (294) with different substituted phenacyl bromide derivatives in ethanol afforded 6-substituted-3-(4-(methylsulfonyl)benzyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]-thiadiazines 295ai (Scheme 88). The antimicrobial activity of the synthesized compounds showed that triazolothiadiazines 295b,e,f,h have significant antibacterial and antifungal activities against all the tested microorganisms [111].
Refluxing of different carboxylic acids with thiocarbohydrazides 38 led to 4-amino-3-substituted-1,2,4-triazole-5-thiones 11sv. Treatment of 11sv with phenacyl bromide or chloride derivatives yielded triazolothiadiazines 296299 [112] (Scheme 89). Interestingly, compounds 297b, 299b, and 299c, having either a chloride or fluoro substituent on the phenyl ring, gave better analgesic and anti-inflammatory activities and less ulcerogenic risk, along with minimum lipid peroxidation [112].
Various electrophilic reagents reacted with 206 to give different triazolothiadiazines 300, 302, and 304. Ethyl 2-((4-amino-5-((4-methyl-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)methyl)-4H-1,2,4-triazole-3-yl)thio)acetate 301 was obtained from the reaction of 206 with ethyl bromoacetate which cyclized using sodium methoxide to give triazolothiadiazine 302. However, reacting 206 with ethyl 2-bromoacetate and ethyl-2-chloroacetoacetate gave substituted triazolothiadiazine 300 and ethyl-substituted triazolo-[3,4-b][1,3,4]thiadiazine-7-carboxylate 304, respectively (Scheme 90) [113].
In a similar reaction, the reaction of (3-methylbenzofuran-2-yl)triazolethione 305 with either 2-bromoacetophenone or hydrazonyl halides produced the corresponding 3-(3-methylbenzofuran-2-yl)-triazolothiadiazine 306 and (2-arylhydrazono)triazolothiadiazine derivative 307, respectively [114] (Scheme 91).
It was reported that 1,2,4-triazole-3-thiol 11o reacted with various bromoacetophenone to yield the corresponding 3,6-disubstituted triazolothiadiazine 308ah. The anticancer activity of these compounds was studied against H157 and BHK-21M cell lines showing that compound 308c was a potent inhibitor of H157 cells having 78.6% inhibition and compounds 308a and 308d were potent inhibitors in cancer therapy against BHK-21 cells with 73.3% and 72.6% inhibition, respectively [115] (Scheme 92).
4-Amino-5-(2-methyl-1H-indol-3-yl)-4H-1,2,4-triazole-3-thiol (263) was successfully cyclized to give triazolo[3,4-b][1,3,4]thiadiazine (310) via reacting with 3-chloropentane-2,4-dione through the intermediate 309. Furthermore, diazotization occurred to compound 310 and chlorophenyldiazene to give 311 (Scheme 93) [116].
On reaction of 11a with N′-arylacetohydrazonoyl halides 312 in the presence of sodium ethoxide, the reaction gave the corresponding 1,2,4-triazole-3-yl-2-(naphthalen-2-yl)-N′-arylethanehydrazonothioates 313. Cyclization of 313 in acidic media gave the target compound triazolothiadiazine 314 [117] (Scheme 94).
Refluxing of 11e with N-aryl-2-oxopropanehydrazonoylchloride 315ae afforded (Z)-6-methyl-7-(2-aryllhydrazono)-3-(trifluoromethyl)-7H-[1,2,4]triazolo[3,4-b]-[1,3,4]thiadiazine (317) via the formation of intermediate 316 [118]. Screening of the anticancer activities revealed that compounds 316a,e were the most active inhibitors against HEPG-2 cell line, whereas compound 316a was active against HCT cell line [118] (Scheme 95).

4. Conclusions

In this review, we are trying to focus attention on the routes of triazole-thione synthesis. Since, triazolethione-thiols have gained considerable importance in medicinal chemistry, due to their broad spectrum as antiviral, antibacterial, anticancer, etc. agents, their synthesis has become of great interest. We also give spots on the biology of the target molecule as prospective antiviral drugs.

Author Contributions

Writing, editing, and submitting, A.A.A.; supervision, A.A.H.; draft writing, M.M.M.; writing and editing, S.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Acknowledgments

Authors acknowledge support by the KIT-Publication Fund of the Karlsruhe Institute of Technology.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Vijesh, A.M.; Isloor, A.M.; Shetty, P.; Sundershan, S.; Fun, H.K. New pyrazole derivatives containing 1,2,4-triazoles and benzoxazoles as potent antimicrobial and analgesic agents. Eur. J. Med. Chem. 2013, 62, 410–415. [Google Scholar] [CrossRef] [PubMed]
  2. Plech, T.; Kaproń, B.; Łuszczki, J.J.; Paneth, A.; Siwek, A.; Kołaczkowski, M.; Żołnierek, M.; Nowak, G. Studies on the anticonvulsant activity of 4-alkyl-1,2,4-triazole-3-thiones and their effect on GABAergic system. Eur. J. Med. Chem. 2014, 86, 690–699. [Google Scholar] [CrossRef] [PubMed]
  3. Abuo-Rahma, G.E.-D.A.; Abdel-Aziz, M.; Beshr, E.A.; Ali, T.F. 1,2,4-Triazole/oxime hybrids as new strategy for nitric oxide donors: Synthesis, anti-inflammatory, ulceroginicity and antiproliferative activities. Eur. J. Med. Chem. 2014, 71, 185–198. [Google Scholar] [CrossRef] [PubMed]
  4. Krishna, K.M.; Inturi, B.; Pujar, G.V.; Purohit, M.N.; Vijaykumar, G. Design, synthesis and 3D-QSAR studies of new diphenylamine containing 1,2,4-triazoles as potential antitubercular agents. Eur. J. Med. Chem. 2014, 84, 516–529. [Google Scholar] [CrossRef]
  5. Tozkoparan, B.; Küpeli, E.; Yeşilada, E.; Ertan, M. Preparation of 5-aryl-3-alkylthio-l,2,4-triazoles and corresponding sulfones with antiinflammatory—Analgesic activity. Biorg. Med. Chem. 2007, 15, 1808–1814. [Google Scholar] [CrossRef]
  6. Sarafianos, S.G.; Marchand, B.; Das, K.; Himmel, D.M.; Parniak, M.A.; Hughes, S.H.; Arnold, E. Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanisms of Polymerization and Inhibition. J. Mol. Biol. 2008, 385, 693–713. [Google Scholar] [CrossRef] [Green Version]
  7. Mishra, C.B.; Mongre, R.K.; Kumari, S.; Jeong, D.K.; Tiwari, M. Novel Triazole-Piperazine Hybrid Molecules Induce Apoptosis via Activation of the Mitochondrial Pathway and Exhibit Antitumor Efficacy in Osteosarcoma Xenograft Nude Mice Model. ACS Chem. Biol. 2017, 17, 753–768. [Google Scholar] [CrossRef]
  8. Colanceska-Ragenovic, K.; Dimova, V.; Kakurinov, V.; Molnar, D.; Buzarovska, A. Synthesis, Antibacterial and Antifungal Activity of 4-Substituted-5-Aryl-1,2,4-Triazoles. Molecules 2001, 6, 815–824. [Google Scholar] [CrossRef] [Green Version]
  9. Xu, Z.; Zhao, S.-J.; Liu, Y. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. Eur. J. Med. Chem. 2019, 183, 111700–111713. [Google Scholar] [CrossRef]
  10. Cai, S.; Li, Q.-S.; Borchardt, R.T.; Kuczera, K.; Schowen, R.L. The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-l-homocysteine hydrolase from Trypanosoma cruzi. Biorg. Med. Chem. 2007, 15, 7281–7287. [Google Scholar] [CrossRef] [Green Version]
  11. Groll, A.H.; Walsh, T.J. Antifungal chemotherapy: Advances and perspectives. Swiss Med. Wkl. 2002, 132, 303–311. [Google Scholar]
  12. Ghannoum, M.A.; Rice, L.B. Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance. Clin. Microbiol. Rev. 1999, 12, 501–517. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Buzdar, A.U.; Robertson, J.F.; Eiermann, W.; Nabholtz, J.M. An Overview of the Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors Anastrozole, Letrozole, and Exemestane. Cancer Interdiscip. Int. J. Am. Cancer Soc. 2002, 95, 2006–2014. [Google Scholar] [CrossRef] [PubMed]
  14. Geisler, J.; Helle, H.; Ekse, D.; Duong, N.K.; Evans, D.B.; Nordbø, Y.; Aas, T.; Lønning, P.E. Letrozoleis Superior to Anastrozolein Suppressing Breast Cancer Tissue and Plasma Estrogen Level. Clin. Cancer Res. 2008, 14, 6330–6336. [Google Scholar] [CrossRef] [Green Version]
  15. Küçükgüzel, Ş.G.; Çıkla-Süzgün, P. Recent advances bioactive 1,2,4-triazole-3-thiones. Eur. J. Med. Chem. 2015, 97, 830–870. [Google Scholar] [CrossRef]
  16. Küçükgüzel, İ.; Rollas, S.; Çevikbaş, A. Synthesis and characterization of certain thiourea derivatives starting from 1,2,4-triazoline-3-thiones as potential antibacterial and antifungal agents. Drug Metabol. Drug Interact. 1995, 12, 151–160. [Google Scholar] [CrossRef]
  17. Franklim, T.N.; Freire-de-Lima, L.; de Nazareth Sá Diniz, J.; Previato, J.; Castro, R.; Mendonça-Previato, L.; de Lima, M. Design, Synthesis and Trypanocidal Evaluation of Novel 1,2,4-Triazoles-3-thiones Derived from Natural Piperine. Molecules 2013, 18, 6366–6382. [Google Scholar] [CrossRef]
  18. Hassan, G.S.; El-Messery, S.M.; Al-Omary, F.A.; Al-Rashood, S.T.; Shabayek, M.I.; Abulfadl, Y.S.; Habib, E.-S.E.; El-Hallouty, S.M.; Fayad, W.; Mohamed, K.M. Nonclassical antifolates, part 4. 5-(2-Aminothiazol-4-yl)-4-phenyl-4H-1,2,4-triazole-3-thiols as a new class of DHFR inhibitors: Synthesis, biological evaluation and molecular modeling study. Eur. J. Med. Chem. 2013, 66, 135–145. [Google Scholar] [CrossRef]
  19. Boraei, A.T.; Gomaa, M.S.; El Sayed, H.; Duerkop, A. Design, selective alkylation and X-ray crystal structure determination of dihydro-indolyl-1,2,4-triazole-3-thione and its 3-benzylsulfanyl analogue as potent anticancer agents. Eur. J. Med. Chem. 2017, 125, 360–371. [Google Scholar] [CrossRef]
  20. Aouad, M.R.; Mayaba, M.M.; Naqvi, A.; Bardaweel, S.K.; Al-blewi, F.F.; Messali, M.; Rezki, N. Design, synthesis, in silico and in vitro antimicrobial screenings of novel 1,2,4-triazoles carrying 1,2,3-triazole scaffold with lipophilic side chain tether. Chem. Cent. J. 2017, 11, 117–123. [Google Scholar] [CrossRef] [Green Version]
  21. Timur, İ.; Kocyigit, Ü.M.; Dastan, T.; Sandal, S.; Ceribası, A.O.; Taslimi, P.; Gulcin, İ.; Koparir, M.; Karatepe, M.; Çiftçi, M.J. In vitro cytotoxic and in vivo antitumoral activities of some aminomethyl derivatives of 2,4-dihydro-3H-1,2,4-triazole-3-thiones—Evaluation of their acetylcholinesterase and carbonic anhydrase enzymes inhibition profiles. Biochem. Mol. Toxicol. 2019, 33, 22239–22250. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Kaproń, B.; Łuszczki, J.J.; Płazińska, A.; Siwek, A.; Karcz, T.; Gryboś, A.; Nowak, G.; Makuch-Kocka, A.; Walczak, K.; Langner, E. Development of the 1,2,4-triazole-based anticonvulsant drug candidates acting on the voltage-gated sodium channels. Insights from in-vivo, in-vitro, and in-silico studies. Eur. J. Pharm. Sci. 2019, 129, 42–57. [Google Scholar] [CrossRef] [PubMed]
  23. Küçükgüzel, I.; Tatar, E.; Küçükgüzel, Ş.G.; Rollas, S.; De Clercq, E. Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. Eur. J. Med. Chem. 2008, 43, 381–392. [Google Scholar] [CrossRef]
  24. Sun, X.H.; Tao, Y.; Liu, Y.F.; Chen, B.; Jia, Y.Q.; Yang, J.W. Synthesis and Biological Activities of Alkyl Substituted Triazolethione Schiff Base. Chin. J. Chem. 2008, 26, 1133–1136. [Google Scholar] [CrossRef]
  25. Luszczki, J.J.; Plech, T.; Wujec, M. Effect of 4-(4-bromophenyl)-5-(3-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol. 2012, 690, 99–106. [Google Scholar] [CrossRef]
  26. Tozkoparan, B.; Kuepeli, E.; Yesilada, E.; Isik, S.; Oezalp, M.; Ertan, M. Synthesis and Evaluation of Analgesic/Anti-inflammatory and Antimicrobial Activities of 3-Substituted-1,2,4-triazole-5-thiones. Arzneimittelforschung 2005, 55, 533–540. [Google Scholar] [CrossRef] [PubMed]
  27. Idrees, M.N., R. D.; Siddiqui, N.J. Synthesis of S-Phenacylated Trisubstituted 1,2,4-Triazole Incorporated with 5-(Benzofuran-2-yl)-1-Phenyl-1H-Pyrazol-3-yl Moiety and their Antibacterial Screening. Der Chemica Sinica 2016, 7, 28–35. [Google Scholar]
  28. Hanif, M.; Saleem, M.; Hussain, M.T.; Rama, N.H.; Zaib, S.; Aslam, M.A.M.; Jones, P.G.; Iqbal, J. Synthesis, Urease Inhibition, Antioxidant and Antibacterial Studies of Some 4-Amino-5-aryl-3H-1,2,4-triazole-3-thiones and their 3,6-Disubstituted 1,2,4-Triazolo[3,4-b]1,3,4-thiadiazole Derivatives. J. Braz. Chem. Soc. 2012, 23, 854–860. [Google Scholar] [CrossRef] [Green Version]
  29. Li, Z.; Gu, Z.; Yin, K.; Zhang, R.; Deng, Q.; Xiang, J. Synthesis of substituted-phenyl-1,2,4-triazol-3-thione Analogues with Modified D-glucopyranosyl Residues and Their Antiproliferative Activities. Eur. J. Med. Chem. 2009, 44, 4716–4720. [Google Scholar] [CrossRef]
  30. Özadalı, K.; Özkanlı, F.; Jain, S.; Rao, P.P.N.; Velázquez-Martínez, C.A. Synthesis and biological evaluation of isoxazolo[4,5-d]pyridazin-4-(5H)-one analogues as potent anti-inflammatory agents. Biorg. Med. Chem. 2012, 20, 2912–2922. [Google Scholar] [CrossRef]
  31. Kanagarajan, V.; Thanusu, J.; Gopalakrishnan, M. Synthesis and in vitro microbiological evaluation of novel 2,4-diaryl-3-azabicyclo[3.3.1]nonan-9,5′-spiro-1′,2′,4′-triazolidine-3′-thiones. Med. Chem. Res. 2012, 21, 3965–3977. [Google Scholar] [CrossRef]
  32. Patil, P.B.; Patil, J.D.; Korade, S.N.; Kshirsagar, S.D.; Govindwar, S.P.; Pore, D.M. An efficient synthesis of anti-microbial 1,2,4-triazole-3-thiones promoted by acidic ionic liquid. Res. Chem. Intermed. 2016, 42, 4171–4180. [Google Scholar] [CrossRef]
  33. Hassan, A.A.; Mohamed, N.K.; Aly, A.A.; Tawfeek, H.N.; Bräse, S.; Nieger, M. Eschenmoser-Coupling Reaction Furnishes Diazenyl-1,2,4-triazole-5(4H)-thione Derivatives. ChemisyrySelect 2019, 4, 465–468. [Google Scholar] [CrossRef]
  34. Sun, X.H.; Tao, Y.; Liu, Y.F.; Chen, B. Synthesis and Biological Activities of Substituted Triazolethione Schiff Base. Chin. J. Chem. 2007, 25, 1573–1576. [Google Scholar] [CrossRef]
  35. Hanif, M.; Hassan, M.; Rafiq, M.; Abbas, Q.; Ishaq, A.; Shahzadi, S.; Seo, S.-Y.; Saleem, M. Microwave-Assisted Synthesis, In Vivo Anti-Inflammatory and In Vitro Anti-Oxidant Activities, and Molecular Docking Study of New Substituted Schiff Base Derivatives. Pharm. Chem. J. 2018, 52, 424–437. [Google Scholar] [CrossRef]
  36. Al-Wahaibi, L.H.; Abu-Melha, H.M.; Ibrahim, D.A. Synthesis and Biochemical Evaluation of Novel Coumarin Derivatives as Anticancer and Anti-HIV Inhibitors Targeting CDK2. J. Chem. 2018, 2018-2023–2023. [Google Scholar]
  37. Wang, B.L.; Liu, X.H.; Zhang, X.L.; Zhang, J.F.; Song, H.B.; Li, Z.M. Synthesis, Structure and Biological Activity of Novel 1,2,4-Triazole Mannich Bases Containing a Substituted Benzylpiperazine Moiety. Chem. Boil. Drug Des. 2011, 78, 42–56. [Google Scholar] [CrossRef]
  38. Sumangala, V.; Poojary, B.; Chidananda, N.; Arulmoli, T.; Shenoy, S. Synthesis and biological evaluation of some Schiff bases of 4-amino-5-(4-methylsulfonyl)benzyl-2,4-dihydro-3H-[1,2,4]-triazole-3-thione. Med. Chem. Res. 2013, 22, 2921–2928. [Google Scholar] [CrossRef]
  39. Süleymanoğlu, N.; Ustabaş, R.; Direkel, Ş.; Alpaslan, Y.B.; Ünver, Y.J. 1,2,4-triazole derivative with Schiff base; thiol-thione tautomerism, DFT study and antileishmanial activity. J. Mol. Struct. 2017, 1150, 82–87. [Google Scholar] [CrossRef]
  40. Bekircan, O.; Bektas, H. Synthesis of New Bis-1,2,4-Triazole Derivatives. Molecules 2006, 11, 469–477. [Google Scholar] [CrossRef] [PubMed]
  41. Raouf, H.; Beyramabadi, S.A.; Allameh, S.; Morsali, A. Synthesis, experimental and theoretical characterizations of a 1,2,4-triazole Schiff base and its nickel(II) complex. J. Mol. Struct. 2019, 1179, 779–786. [Google Scholar] [CrossRef]
  42. Jha, A.; Murthy, Y.; Durga, G. Synthesis, characterization and bioactivity of transition metal complexes of new 3-methyl-5-mercapto-4-triazole Schiff bases. Res. J. Pharm. Biol. Chem. Sci. 2015, 6, 1306–1315. [Google Scholar]
  43. Haddad, R.; Yousif, E.; Ahmed, A. Synthesis and characterization of transition metal complexes of 4-Amino-5-pyridyl-4H-1,2,4-triazole-3-thiol. SpringerPlus 2013, 2, 510–519. [Google Scholar] [CrossRef] [Green Version]
  44. Kikuta, E.; Aoki, S.; Kimura, E.J. New potent agents binding to a poly(dT) sequence in double-stranded DNA: Bis(Zn2+-cyclen) and tris(Zn2+-cyclen) complexes. Bio. Inorg. Chem. 2002, 7, 473–482. [Google Scholar] [CrossRef] [PubMed]
  45. Karegoudar, P.; Prasad, D.J.; Ashok, M.; Mahalinga, M.; Poojary, B.; Holla, B.S. Synthesis, antimicrobial and anti-inflammatory activities of some 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles and 1,2,4-triazolo[3,4-b][1,3,4]thiadiazines bearing trichlorophenyl moiety. Eur. J. Med. Chem. 2008, 43, 808–815. [Google Scholar] [CrossRef] [PubMed]
  46. Khanum, S.A.; Shashikanth, S.; Umesha, S.; Kavitha, R. Synthesis and antimicrobial study of novel heterocyclic compounds from hydroxybenzophenones. Eur. J. Med. Chem. 2005, 40, 1156–1162. [Google Scholar] [CrossRef]
  47. Amir, M.; Kumar, H.; Javed, S. Condensed bridgehead nitrogen heterocyclic system: Synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid. Eur. J. Med. Chem. 2008, 43, 2056–2066. [Google Scholar] [CrossRef]
  48. Ziaie, M.; Akbaridilmaghani, K.; Tukmechi, A. Synthesis and Biological Evaluation of 1,2,4-Triazoles and 1,3,4-Oxadiazoles Derivatives Linked to 1,4-Dihydropyridines Scaffold. Acta Chim. Slov. 2017, 64, 895–901. [Google Scholar] [CrossRef]
  49. Behalo, M.S.; Amine, A.M.; Fouda, I.M. Regioselective synthesis, antitumor and antioxidant activities of some 1,2,4-triazole derivatives based on 4-phenyl-5-(quinolin-8-yloxy)methyl-4H-1,2,4-triazole-3-thiol. Phosphorus Sulfur Silicon Relat. Elem. 2017, 192, 410–417. [Google Scholar] [CrossRef]
  50. Arrowsmith, R.L.; Waghorn, P.A.; Jones, M.W.; Bauman, A.; Brayshaw, S.K.; Hu, Z.; Kociok-Köhn, G.; Mindt, T.L.; Tyrrell, R.M.; Botchway, S.W. Fluorescent gallium and indium bis(thiosemicarbazonates) and their radiolabelled analogues: Synthesis, structures and cellular confocal fluorescence imaging investigations. Dalton Trans. 2011, 40, 6238–6252. [Google Scholar] [CrossRef]
  51. Wang, B.-L.; Zhang, L.-Y.; Liu, X.-H.; Ma, Y.; Zhang, Y.; Li, Z.-M.; Zhang, X. Synthesis, biological activities and SAR studies of new 3-substitutedphenyl-4-substitutedbenzylideneamino-1,2,4-triazole Mannich bases and bis-Mannich bases as ketol-acid reductoisomerase inhibitors. Bioorg. Med. Chem. Lett. 2017, 27, 5457–5462. [Google Scholar] [CrossRef] [PubMed]
  52. Ramesh, R.; Lalitha, A. Facile and Green Chemistry Access to 5-aryl-1,2,4-Triazolidine-3-thiones in Aqueous Medium. Chem. Select 2016, 1, 2085–2094. [Google Scholar] [CrossRef]
  53. Wang, Q.P.; Zhang, J.Q.; Damu, G.L.V.; Wan, K.; Zhang, H.Z.; Zhou, C.H. Synthesis and biological activities of thio-triazole derivatives as novel potential antibacterial and antifungal agents. Sci. China Chem. 2012, 55, 2134–2153. [Google Scholar] [CrossRef]
  54. Mane, M.; Pore, D. A novel one pot multi-component strategy for facile synthesis of 5-aryl-[1,2,4]triazolidine-3-thiones. Tetrahedron Lett. 2014, 55, 6601–6604. [Google Scholar] [CrossRef]
  55. Özdemir, A.; Turan-Zitouni, G.; Asim Kaplancikli, Z.; Chevallet, P.J. Synthesis of some 4-arylidenamino-4H-1,2,4-triazole-3-thiols and their antituberculosis activity. J. Enzym. Inhib. Med. Chem. 2007, 22, 511–523. [Google Scholar] [CrossRef]
  56. Godhani, D.R.; Sanja, D.B.; Sanghani, A.M. Synthesis and antimicrobial elucidation of [1,2,4]-triazole-3-thione derivatives. J. Chem. Pharm. Res. 2013, 5, 240–243. [Google Scholar]
  57. Coşkun, G.P.; Djikic, T.; Hayal, T.B.; Türkel, N.; Yelekçi, K.; Şahin, F.; Küçükgüzel, Ş.G. Synthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme Inhibitors. Molecules 2018, 23, 1969. [Google Scholar] [CrossRef] [Green Version]
  58. Bulut, N.; Kocyigit, U.M.; Gecibesler, I.H.; Dastan, T.; Karci, H.; Taslimi, P.; Durna Dastan, S.; Gulcin, I.; Cetin, A.J. Synthesis of some novel pyridine compounds containing bis-1,2,4-triazole/thiosemicarbazide moiety and investigation of their antioxidant properties, carbonic anhydrase, and acetylcholinesterase enzymes inhibition profiles. Biochem. Mol. Toxicol. 2018, 32, 22006–220016. [Google Scholar] [CrossRef]
  59. Shanmugapriya, A.; Dallemer, F.; Prabhakaran, R. Synthesis, characterisation, crystal structures and biological studies of palladium(II) complexes containing 5-(2-hydroxy-3-methoxy-phenyl)-2,4-dihydro[1,2,4]triazole-3-thione derivatives. New J. Chem. 2018, 42, 18850–18864. [Google Scholar] [CrossRef]
  60. Wang, B.-L.; Zhang, L.-Y.; Zhan, Y.-Z.; Zhang, Y.; Zhang, X.; Wang, L.-Z.; Li, Z.-M. Synthesis and biological activities of novel 1,2,4-triazole thiones and bis(1,2,4-triazole thiones) containing phenylpyrazole and piperazine moieties. J. Fluorine Chem. 2016, 184, 36–44. [Google Scholar] [CrossRef]
  61. Barbuceanu, S.F.; Olaru, O.T.; Nitulescu, G.M.; Draghici, C.; Socea, L.I.; Barbuceanu, F.; Enache, C.; Saramet, G. New Heterocyclic Compounds from 1,2,4-triazoles Class with Potential Cytotoxic Activity. Rev. Chim. 2018, 69, 2346–2356. [Google Scholar] [CrossRef]
  62. Mlostoń, G.; Pieczonka, A.M.; Wróblewska, A.; Linden, A.; Heimgartner, H. Studies on the synthesis and some reactions of (S)-proline hydrazides. Tetrahedron Asymm. 2012, 23, 795–801. [Google Scholar] [CrossRef] [Green Version]
  63. Pieczonka, A.M.; Mlostoń, G.; Heimgartner, H. Synthesis of Bis-Heterocyclic 1H-Imidazole 3-Oxides from 3-Oxido-1H-imidazole-4-carbohydrazides. Helv. Chim. Acta 2012, 95, 404–414. [Google Scholar] [CrossRef] [Green Version]
  64. Ezabadi, I.R.; Camoutsis, C.; Zoumpoulakis, P.; Geronikaki, A.; Soković, M.; Glamočilija, J.; Ćirić, A. Sulfonamide-1,2,4-triazole derivatives as antifungal and antibacterial agents: Synthesis, biological evaluation, lipophilicity, and conformational studies. Biorg. Med. Chem. 2008, 16, 1150–1161. [Google Scholar] [CrossRef] [PubMed]
  65. Sujith, K.; Rao, J.N.; Shetty, P.; Kalluraya, B. Regioselective reaction: Synthesis and pharmacological study of Mannich bases containing ibuprofen moiety. Eur. J. Med. Chem. 2009, 44, 3697–3702. [Google Scholar] [CrossRef]
  66. Gouranourimi, A.; Ghassemzadeh, M.; Bahemmat, B. Bernhard Neumüller. New palladium(II) complexes containing 3-mercapto-1,2,4-triazole ligands: Synthesis, characterization, crystal structure, and density functional theory calculations. Monatheft Chem. 2015, 146, 5767–5775. [Google Scholar]
  67. Gao, Y.; Na, L.X.; Xu, Z.; Zhang, S.; Wang, A.P.; Lü, K.; Guo, H.Y.; Liu, M.L. Design, Synthesis and Antibacterial Evaluation of 1-[(1R,S)-2-Fluorocyclopropyl]ciprofloxacin-1,2,4-triazole-5(4H)-thione Hybrids. Chem. Biodivers. 2018, 15, 1800261–1800270. [Google Scholar] [CrossRef] [PubMed]
  68. Gavrilova, E.; Krutov, I.; Valieva, A.; Khayarov, K.R.; Samigullina, A.; Gubaidullin, A.; Shatalova, N.; Burangulova, R.; Sinyashin, O. Synthesis of New Phosphorylated 1,2,4-Triazole-3-thiones. N,S-Functionalization Methods. Russ. J. Gen. Chem. 2018, 88, 2269–2275. [Google Scholar] [CrossRef]
  69. Abdel-Wahab, B.F.; Abdel-Aziz, H.A.; Ahmed, E.M. Synthesis and antimicrobial evaluation of 1-(benzofuran-2-yl)-4-nitro-3-arylbutan-1-ones and 3-(benzofuran-2-yl)-4,5-dihydro-5-aryl-1-[4-(aryl)-1,3-thiazol-2-yl]-1H-pyrazoles. Eur. J. Med. Chem. 2009, 44, 2632–2635. [Google Scholar] [CrossRef]
  70. Tehrani, K.H.M.E.; Mashayekhi, V.; Azerang, P.; Minaei, S.; Sardari, S.; Kobarfard, F. Synthesis and Antimycobacterial Activity of some Triazole Derivatives-New Route to Functionalized Triazolopyridazines. Iran. J. Pharm. Res. 2015, 14, 59–72. [Google Scholar]
  71. Siddiqui, N.; Ahsan, W. Triazole incorporated thiazoles as a new class of anticonvulsants: Design, synthesis and in vivo screening. Eur. J. Med. Chem. 2010, 45, 1536–1543. [Google Scholar] [CrossRef] [PubMed]
  72. Ye, X.-X.; Chen, Z.-F.; Zhang, A.-J.; Zhang, L.-X. Synthesis and Biological Evaluation of Some Novel Schiff’s Bases from 1,2,4-Triazole. Molecules 2007, 12, 1202–1209. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Al-Abdullah, E.S.; Asiril, H.H.; Lahsasni, S.; Habib, E.E.; Ibrahim, T.M.; El-emam, A.A. Synthesis, antimicrobial, and anti-inflammatory activity, of novel S-substituted and N-substituted 5-(1-adamantyl)-1,2,4-triazole-3-thiols. Drug Des. Dev. Ther. 2014, 8, 505–518. [Google Scholar]
  74. Hassan, A.A.; Mourad, A.E.; Abou-Zied, A.H. Benzo- and naphthoimidazoxadiazolediene, naphthobisthiazole as well as naphthothiazine derivatives from 1-acylthiosemicarbazides. Arkivoc 2007, 2007, 222–235. [Google Scholar]
  75. Zaki, R.M.; Kamal El-Dean, A.M.; Radwan, S.M.; Saber, A.F. Efficient synthesis, reactions and spectral characterization of pyrazolo [4′,3′:4,5] thieno [3, 2-d] pyrimidines and related heterocycles. Heterocycl. Commun. 2019, 25, 39–46. [Google Scholar] [CrossRef]
  76. Hassan, A.A.; Ibrahim, Y.R.; Shawky, A.M.; Döpp, D. Reaction of 4-substituted thiosemicarbazides with (2,4,7-trinitro-9H -fluoren-9-ylidene)propanedinitrile. J. Heterocycl. Chem. 2006, 43, 849. [Google Scholar] [CrossRef]
  77. Shamsuzzamzn; Siddiqui, N.; Salim, A.; Akram, M. Manganese Dioxide Mediated Stereoselective, One-step Synthesis of Novel Steroidal (6R )-Spiro-1’,2′,4′-triazoline-3′-thiones. Chin. J. Chem. 2009, 27, 1523. [Google Scholar] [CrossRef]
  78. Pore, D.M.; Hegade, P.G.; Mane, M.M.; Patil, J.D. The unprecedented synthesis of novel spiro-1, 2, 4-triazolidinones. RSC Adv. 2013, 3, 25723–25726. [Google Scholar] [CrossRef]
  79. Shamsuzzaman; Salim, A.; Aslam, M.; Naqvi, F. Synthesis of Steroidal Spiro-1′,2′,4′-triazolidine-3′-thiones. Synth. Commun. 1997, 27, 2171–2175. [Google Scholar] [CrossRef]
  80. Gopalakrishnan, M.; Kanagarajan, V.; Thanusu, J. Novel one-pot synthesis of 1,2,4-triazolidin-3-thiones comprising piperidine moiety. Green Chem. Lett. Rev. 2008, 1, 241–248. [Google Scholar] [CrossRef]
  81. Kabilan, S.; Umamatheswari, S. Synthesis, characterisation and antimicrobial activities of novel 7,9-diphenyl-1, 2, 4-triaza-8-oxa-spiro [4.5]-decan-3-thiones. Med. Chem. Res. 2011, 20, 542–545. [Google Scholar] [CrossRef]
  82. Aly, A.A.; Hassan, A.A.; Mohamed, N.K.; El-Shaieb, K.M.; Makhlouf, M.M.; Bräse, S.; Nieger, M. Reactive intermediates in the reaction of hydrazinecarbothioamides with 2-(bis(methylthio)methylene)malononitrile and ethyl 2-cyano-3,3-bis(methylthio)acrylate. Res. Chem. Intermed. 2019, 45, 613–631. [Google Scholar] [CrossRef] [Green Version]
  83. Chebabe, D.; Dermaj, A.; El Abidine Ait Chikh, Z.; Hajjaji, N.; Rico-Lattes, I.; Lattes, A. Synthesis of New Surfactants Mono and Bipolar Derived from 1,2,4-Triazole-5-thione. Synth. Commun. 2004, 34, 4189–4198. [Google Scholar] [CrossRef]
  84. Vainilavicius, P.; Smicius, R.; Jakubkiene, V.; Tumkevicius, S. Synthesis of 5-(6-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-3-pyrimidinyl)-methyl-4-amino-1,2,4-triazole-3-thione and its Reactions with Polyfunctional Electrophiles. Monatsh. Chem. 2001, 132, 825–831. [Google Scholar] [CrossRef]
  85. Ahmad, A.; Varshney, H.; Rauf, A.; Sherwani, A.; Owais, M. Synthesis and anticancer activity of long chain substituted 1,3,4-oxadiazol-2-thione, 1,2,4-triazol-3-thione and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine derivatives. Arab. J. Chem. 2017, 10, 3347–3357. [Google Scholar] [CrossRef] [Green Version]
  86. Aouad, A.R.; Soliman, M.A.; Alharbi, M.O.; Bardaweel, S.K.; Sahu, P.K.; Ali, A.A.; Messali, M.; Rezki, N.; Al-Soud, Y.A. Design, Synthesis and Anticancer Screening of Novel Benzothiazole-Piperazine-1,2,3-Triazole Hybrids. Molecules 2018, 23, 2788. [Google Scholar] [CrossRef] [Green Version]
  87. Kuş, C.; Ayhan-Kılcıgil, G.; Özbey, S.; Kaynak, F.B.; Kaya, M.; Çoban, T.; Can-Eke, B. Synthesis and antioxidant properties of novel N-methyl-1,3,4-thiadiazol-2-amine and 4-methyl-2H-1,2,4-triazole-3(4H)-thione derivatives of benzimidazole class. Biorg. Med. Chem. 2008, 16, 4294–4303. [Google Scholar] [CrossRef]
  88. Rao, D.V.N.; Prasad, A.R.G.; Spoorthy, Y.N.; Rao, D.R.; Ravindranath, L.R.K.R. Synthesis, Characterization and Antimicrobial Evaluation of Substituted 1,2,4-Triazole Thiones Containing Pyrazole Moiety. J. Clin. Anal. Med. 2015, 6, 590–598. [Google Scholar] [CrossRef] [Green Version]
  89. Fahmy, H.H.; Khalifa, N.M.; Nossier, E.S.; Abdalla, M.M.; Ismail, M.M. Synthesis and anti-inflammatory evaluation of new substituted 1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazole derivatives. Acta Pol. Pharm. 2012, 69, 411–421. [Google Scholar]
  90. Yunus, U.; Bhatti, M.H.; Rahman, N.; Mussarat, N.; Asghar, S.; Masood, B. Synthesis, Characterization, and Biological Activity of Novel Schiff and Mannich Bases of 4-Amino-3-(N-phthalimidomethyl)-1,2,4-triazole-5-thione. J. Chem. 2013, 2013, 638520–638530. [Google Scholar] [CrossRef]
  91. Tiwari, J.; Saquib, M.; Singh, S.; Tufail, F.; Singh, J.; Singh, J. Catalyst-free glycerol-mediated green synthesis of 5′-thioxospiro[indoline-3,3′-[1,2,4]triazolidin]-2-ones/spiro[indoline-3,3′-[1,2,4]triazolidine]-2,5′-diones. Synth. Commun. 2017, 47, 1999–2006. [Google Scholar] [CrossRef]
  92. Shaker, S.; Marzouk, M.I. Utilization of Cyanoacetohydrazide and Oxadiazolyl Acetonitrile in the Synthesis of Some New Cytotoxic Heterocyclic. Molecules 2016, 21, 155. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Siddiqui, N.; Salim, A.; Akram, M. Manganese Dioxide Mediated Stereoselective, One-step Synthesis of Novel Steroidal (6R)-Spiro-1′,2′,4′-triazoline-3′-thiones. Chin. J. Chem. 2009, 27, 1523–1525. [Google Scholar]
  94. Gopalakrishnan, M.; Thanusu, J.; Kanagarajan, V.; Govindaraju., J. Design, Synthesis and in Vitro Microbiological Evaluation of 6,6-dimethyl-7,9-diaryl-1,2,4,8-tetraazaspiro[4.5]decan-3-thiones--a New Series of ‘Tailor-Made’ Compounds. J. Enzym. Inhib. Med. Chem. 2009, 24, 406–415. [Google Scholar] [CrossRef] [PubMed]
  95. Khalil, N.S.A.M. Efficient Synthesis, Structure, and Antimicrobial Activity of Some Novel N- And S-beta-D-glucosides of 5-pyridin-3-yl-1,2,4-triazoles. Carbohydr. Res. 2006, 341, 2187–2199. [Google Scholar] [CrossRef]
  96. Popiołek, Ł.; Kosikowska, U.; Dobosz, M.; Malm, A. Synthesis and Antimicrobial Properties of New Thiosemicarbazide, 1,2,4-Triazole, and 1,3,4-Thiadiazole Derivatives of Sulfanylacetic Acid. Phosphorous Sulfur Silicon Relat. Elem. 2012, 187, 468–481. [Google Scholar] [CrossRef]
  97. Hunashal, R.; Satyanarayana, D.; Maddi, V. Synthesis and Antimicrobial Activity of 2-[4-(Substituted Benzylidenamino)-5-(Substituted Phenoxymethyl)-4H-1,2,4-Triazol-3-yl thio] Acetic Acid Derivatives. J. Chem. 2012, 9, 1206–1210. [Google Scholar] [CrossRef]
  98. Ji, D.; Lu, J.; Lu, B.; Xin, C.; Mu, J.; Li, J.; Peng, C.; Bao, X. Efficient Synthesis and Antimicrobial Activity of Some Novel S-β-D-glucosides of 5-aryl-1,2,4-triazole-3-thiones Derivatives. Bioorg. Med. Chem. Lett. 2013, 23, 1997–2000. [Google Scholar] [CrossRef]
  99. Popiołek, Ł.; Biernasiuk, A.; Paruch, K.; Malm, A.; Wujec, M. Synthesis and in vitro antimicrobial activity screening of new pipemidic acid derivatives. Arch. Pharm. Res. 2018, 41, 633–645. [Google Scholar] [CrossRef] [Green Version]
  100. Barbuceanu, S.-F.; Ilies, D.C.; Saramet, G.; Uivarosi, V.; Draghici, C.; Radulescu, V. Synthesis and Antioxidant Activity Evaluation of New Compounds from Hydrazinecarbothioamide and 1,2,4-Triazole Class Containing Diarylsulfone and 2,4-Difluorophenyl Moieties. Int. J. Mol. Sci. 2014, 15, 10908–10925. [Google Scholar] [CrossRef]
  101. Ding, Y.; Zhang, Z.; Zhang, G.; Mo, S.; Li, Q.; Zhao, Z. Green synthesis and evaluation of the antitumor activity of a novel series of 3-[4-bi-(4-fluorophenyl)methylpiperazinyl]-4-amino-5-thione-1,2,4-triazole Schiff bases. Res. Chem. Intermed. 2016, 42, 3105–3116. [Google Scholar] [CrossRef]
  102. Amer, A.A.; Moustafa, A.H. Synthesis of 3-Pyrazolyl-1,2,4-Triazoles via One-Pot Multicomponent Reaction in Phosphoric Acid. Synlett 2016, 27, 1703–1706. [Google Scholar] [CrossRef]
  103. Abdallah, M.A.; Riyadh, S.M.; Abbas, I.M.; Gomha, S.M. Synthesis and Biological Activities of 7-Arylazo-7H-pyrazolo[5,1-c][1,2,4]Triazol-6(5H)-Ones and 7-Arylhydrazono-7H-[1,2,4]triazolo[3,4-b] [1,3,4]thiadiazines. J. Chin. Chem. Soc. 2005, 52, 987–994. [Google Scholar] [CrossRef]
  104. Shah, T.A.; Ahmad, Z.; Mir, N.A.; Muneer, M.; Rath, N.P.; Ahmad, M. One step synthesis of highly functionalized thiazolo[3,2-b][1,2,4]triazole, triazolo[1,5-a]pyrimidine and triazolo[3,4-b][1,3,4]thiadiazine. RSC Adv. 2015, 5, 107931–107937. [Google Scholar] [CrossRef]
  105. Saundane, A.R.; Manjunatha, Y. Synthesis, antimicrobial and antioxidant activities of 2-oxo-6-phenyl-2-yl-4-(2′-phenyl-5′-substituted 1H-indol-3′-yl)-1,2-dihydro pyridin-3-carbonitriles and their derivatives. Arab. J. Chem. 2016, 9, 501–505. [Google Scholar] [CrossRef] [Green Version]
  106. Lesyk, R.; Vladzimirska, O.; Holota, S.; Zaprutko, L.; Gzella, A. New 5-substituted thiazolo[3,2-b][1,2,4]triazol-6-ones: Synthesis and anticancer evaluation. Eur. J. Med. Chem. 2007, 42, 641–648. [Google Scholar] [CrossRef]
  107. Rode, N.D.; Sonawane, A.D.; Garud, D.R.; Joshi, R.R.; Joshi, R.A.; Likhite, A.P. First regioselective iodocyclization reaction of 3-aryl-5-(prop-2-ynylthio)-1H-1,2,4-triazoles. Tetrahedron Lett. 2015, 56, 5140–5144. [Google Scholar] [CrossRef]
  108. Potts, K.T.; Ehlinger, R.; Kanemasa, S.J. Reactions of (chlorocarbonyl)phenylketene. Formation of ring-fused 4H-1,3-thiazinium betaines from heterocyclic thiones. J. Org. Chem. 1980, 45, 2474–2485. [Google Scholar] [CrossRef]
  109. Davoodnia, A.; Ameli, S.; Tavakoli-Hoseini, N. Synthesis of Some Functionalized Thiazolo[3,2-b][1,2,4]triazoles. Asian J. Chem. 2011, 23, 3707–3709. [Google Scholar]
  110. Khan, I.; Zaib, S.; Ibrar, A.; Rama, N.H.; Simpson, J.; Iqbal, J. Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines. Eur. J. Med. Chem. 2014, 78, 167–177. [Google Scholar] [CrossRef]
  111. Almajan, G.L.; Barbuceanu, S.-F.; Bancescu, G.; Saramet, I.; Saramet, G.; Draghici, C. Synthesis and antioxidant activity evaluation of new compounds from hydrazinecarbothioamide and 1,2,4-triazole class containing diarylsulfone and 2,4-difluorophenyl moieties. Eur. J. Med. Chem. 2010, 45, 613–6146. [Google Scholar]
  112. Senthilvelan, A.; Ramakrishnan, V.T. A new base-mediated photocyclization to 1,2,4-triazolo[3,4-b]-1,3-(4H)-benzothiazines via 1,2,4-triazole-3-thiones. Tetrahedron Lett. 2002, 43, 5119–5123. [Google Scholar] [CrossRef]
  113. Senthilvelan, A.; Thirumalai, D.; Ramakrishnan, V. Photochemical synthesis of triazolo[3,4-b]-1,3(4H)-benzothiazines: A detailed mechanistic study on photocyclization/photodesulfurisation of triazole-3-thiones. Tetrahedron 2004, 60, 851–860. [Google Scholar] [CrossRef]
  114. Sumangala, V.; Poojary, B.; Chidananda, N.; Arulmoli, T.; Shenoy, S. Synthesis, crystal structures and electronic properties of isomers of chloro-pyridinylvinyl-1H-indoles. Eur. J. Med. Chem. 2012, 54, 59–64. [Google Scholar] [CrossRef] [PubMed]
  115. Aytaç, S.P.; Tozkoparan, B.; Kaynak, F.B.; Aktay, G.; Göktaş, Ö.; Ünüvar, S. Synthesis of 3,6-disubstituted 7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines as novel analgesic/anti-inflammatory compounds. Eur. J. Med. Chem. 2009, 44, 4528–4540. [Google Scholar] [CrossRef]
  116. Dawood, K.M.; Farag, A.M.; Abdel-Aziz, H.A. Synthesis and antimicrobial evaluation of some 1,2,4-triazole, 1,3,4-oxa(thia)diazole, and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine derivatives. Heteroatom Chem. 2005, 16, 621–627. [Google Scholar] [CrossRef]
  117. Shawali, A.S.; Zeid, I.F.; Abdelkader, M.H.; Elsherbini, A.A.; Altalbawy, F.M.A.J. Synthesis, Acidity Constants and Tautomeric Structure of 7-Arylhydrazono[1,2,4]Triazolo[3,4-b][1,3,4]thiadiazines in Ground and Excited States. Chin. Chem. Soc. 2001, 48, 65–75. [Google Scholar] [CrossRef]
  118. Farghaly, T.A.E.-R.; Abdallah, M.A.; Mahmoud, H.K. Synthesis of novel 1,2,4-triazoles and triazolo-thiadiazines as anticancer agents. Turk. J. Chem. 2015, 39, 955–969. [Google Scholar] [CrossRef]
Figure 1. Structure of anti-HIV active triazole drugs.
Figure 1. Structure of anti-HIV active triazole drugs.
Molecules 25 03036 g001
Figure 2. Some potent drugs containing triazole and triazolethione moieties.
Figure 2. Some potent drugs containing triazole and triazolethione moieties.
Molecules 25 03036 g002
Figure 3. 1,2,4-Triazole thiones.
Figure 3. 1,2,4-Triazole thiones.
Molecules 25 03036 g003
Figure 4. Thione-thiol tautomeric forms.
Figure 4. Thione-thiol tautomeric forms.
Molecules 25 03036 g004
Scheme 1. Synthesis of triazolethiones 10ac.
Scheme 1. Synthesis of triazolethiones 10ac.
Molecules 25 03036 sch001
Scheme 2. Synthesis of triazolethiones 13af.
Scheme 2. Synthesis of triazolethiones 13af.
Molecules 25 03036 sch002
Scheme 3. Synthesis of triazolethiones 19ad.
Scheme 3. Synthesis of triazolethiones 19ad.
Molecules 25 03036 sch003
Scheme 4. Synthesis of triazolethiones 24a,b.
Scheme 4. Synthesis of triazolethiones 24a,b.
Molecules 25 03036 sch004
Scheme 5. Synthesis of triazolethiones 27.
Scheme 5. Synthesis of triazolethiones 27.
Molecules 25 03036 sch005
Scheme 6. Synthesis of triazolethiones 30ac.
Scheme 6. Synthesis of triazolethiones 30ac.
Molecules 25 03036 sch006
Scheme 7. Synthesis of triazolethiones 32ac.
Scheme 7. Synthesis of triazolethiones 32ac.
Molecules 25 03036 sch007
Scheme 8. Synthesis of bis-4-amino-triazolethiones 35ad, 36ad and 37ad.
Scheme 8. Synthesis of bis-4-amino-triazolethiones 35ad, 36ad and 37ad.
Molecules 25 03036 sch008
Scheme 9. Synthesis of triazolethiones 40af.
Scheme 9. Synthesis of triazolethiones 40af.
Molecules 25 03036 sch009
Scheme 10. Synthesis of triazolethiones 42aj.
Scheme 10. Synthesis of triazolethiones 42aj.
Molecules 25 03036 sch010
Scheme 11. Synthesis of triazolethiones 47af.
Scheme 11. Synthesis of triazolethiones 47af.
Molecules 25 03036 sch011
Scheme 12. Synthesis of bis-triazolethiones 51ae.
Scheme 12. Synthesis of bis-triazolethiones 51ae.
Molecules 25 03036 sch012
Scheme 13. Synthesis of triazolethiones 57ad.
Scheme 13. Synthesis of triazolethiones 57ad.
Molecules 25 03036 sch013
Scheme 14. Synthesis of 1,2,4-triazole-3-thiones 63ae.
Scheme 14. Synthesis of 1,2,4-triazole-3-thiones 63ae.
Molecules 25 03036 sch014
Scheme 15. Synthesis of 4-N-amino-triazolethiones 11d,e.
Scheme 15. Synthesis of 4-N-amino-triazolethiones 11d,e.
Molecules 25 03036 sch015
Scheme 16. Synthesis of triazolethiones 66ac.
Scheme 16. Synthesis of triazolethiones 66ac.
Molecules 25 03036 sch016
Scheme 17. Synthesis of glycosides of triazolethiones 69ad.
Scheme 17. Synthesis of glycosides of triazolethiones 69ad.
Molecules 25 03036 sch017
Scheme 18. Synthesis of Pd complexes of triazolethiones 71ad.
Scheme 18. Synthesis of Pd complexes of triazolethiones 71ad.
Molecules 25 03036 sch018
Scheme 19. Synthesis of S-alkylated triazolethiones 76ah.
Scheme 19. Synthesis of S-alkylated triazolethiones 76ah.
Molecules 25 03036 sch019
Scheme 20. Synthesis of triazolethiones 79ae.
Scheme 20. Synthesis of triazolethiones 79ae.
Molecules 25 03036 sch020
Scheme 21. Mechanism describes formation of triazolethiones 79ae.
Scheme 21. Mechanism describes formation of triazolethiones 79ae.
Molecules 25 03036 sch021
Scheme 22. Synthesis of triazolethiones 89ac.
Scheme 22. Synthesis of triazolethiones 89ac.
Molecules 25 03036 sch022
Scheme 23. Synthesis of triazolethione 92a.
Scheme 23. Synthesis of triazolethione 92a.
Molecules 25 03036 sch023
Scheme 24. Synthesis of triazolethiones 97af.
Scheme 24. Synthesis of triazolethiones 97af.
Molecules 25 03036 sch024
Scheme 25. Synthesis of triazolethiones 100af.
Scheme 25. Synthesis of triazolethiones 100af.
Molecules 25 03036 sch025
Scheme 26. Synthesis of imidazolyl-N-oxide-triazolethiones 103ai.
Scheme 26. Synthesis of imidazolyl-N-oxide-triazolethiones 103ai.
Molecules 25 03036 sch026
Scheme 27. Synthesis of pyridazino-triazolethiones 105a,b.
Scheme 27. Synthesis of pyridazino-triazolethiones 105a,b.
Molecules 25 03036 sch027
Scheme 28. Synthesis of triazolethiones 110an.
Scheme 28. Synthesis of triazolethiones 110an.
Molecules 25 03036 sch028
Scheme 29. Synthesis of chromen-2-ones derived by triazolethiones 112ac.
Scheme 29. Synthesis of chromen-2-ones derived by triazolethiones 112ac.
Molecules 25 03036 sch029
Scheme 30. Synthesis of triazolethiones 116ae.
Scheme 30. Synthesis of triazolethiones 116ae.
Molecules 25 03036 sch030
Scheme 31. Synthesis of triazolethione 121.
Scheme 31. Synthesis of triazolethione 121.
Molecules 25 03036 sch031
Scheme 32. Synthesis of 2,4-triazole-5(4H)-thiones 124ad.
Scheme 32. Synthesis of 2,4-triazole-5(4H)-thiones 124ad.
Molecules 25 03036 sch032
Scheme 33. Synthesis of [1,2,4]triazolo-pyrimido[4-b]benzo[5,6][1,4]oxathiino[3,2-g]quinoline-2(3H)-thiones 129.
Scheme 33. Synthesis of [1,2,4]triazolo-pyrimido[4-b]benzo[5,6][1,4]oxathiino[3,2-g]quinoline-2(3H)-thiones 129.
Molecules 25 03036 sch033
Scheme 34. Synthesis of 1,2,4-triazole-5(4H)-thiones 132af.
Scheme 34. Synthesis of 1,2,4-triazole-5(4H)-thiones 132af.
Molecules 25 03036 sch034
Scheme 35. Synthesis of 1,2,4-triazole-thiones of 1-[(1R,2S)-2-fluorocyclopropyl]-CPFX 134ac.
Scheme 35. Synthesis of 1,2,4-triazole-thiones of 1-[(1R,2S)-2-fluorocyclopropyl]-CPFX 134ac.
Molecules 25 03036 sch035
Scheme 36. Synthesis of 1,2,4-triazole-thiones 136.
Scheme 36. Synthesis of 1,2,4-triazole-thiones 136.
Molecules 25 03036 sch036
Scheme 37. Synthesis of 1,2,4-pyrazolothieno[2,3-e][1,2,4]triazolo[1,5-c]pyrimidine-2-thione 140.
Scheme 37. Synthesis of 1,2,4-pyrazolothieno[2,3-e][1,2,4]triazolo[1,5-c]pyrimidine-2-thione 140.
Molecules 25 03036 sch037
Scheme 38. Synthesis of fused triazolothiadiazines 141ad.
Scheme 38. Synthesis of fused triazolothiadiazines 141ad.
Molecules 25 03036 sch038
Scheme 39. Synthesis of triazolethiones 144ai.
Scheme 39. Synthesis of triazolethiones 144ai.
Molecules 25 03036 sch039
Scheme 40. Synthesis of triazolethiones 149ae.
Scheme 40. Synthesis of triazolethiones 149ae.
Molecules 25 03036 sch040
Scheme 41. Synthesis of 3,4,5-trisubstituted-1,2,4-triazoles 157ae.
Scheme 41. Synthesis of 3,4,5-trisubstituted-1,2,4-triazoles 157ae.
Molecules 25 03036 sch041
Scheme 42. Synthesis of triazolethione 159.
Scheme 42. Synthesis of triazolethione 159.
Molecules 25 03036 sch042
Scheme 43. Synthesis of triazolethiones 163ah.
Scheme 43. Synthesis of triazolethiones 163ah.
Molecules 25 03036 sch043
Scheme 44. Synthesis of spiro-triazolethiones 165ac.
Scheme 44. Synthesis of spiro-triazolethiones 165ac.
Molecules 25 03036 sch044
Scheme 45. Synthesis of ethyl 2-(substituted phenyl)-3-thioxo-1,2,4,6,7-pentaazaspiroacetate (168).
Scheme 45. Synthesis of ethyl 2-(substituted phenyl)-3-thioxo-1,2,4,6,7-pentaazaspiroacetate (168).
Molecules 25 03036 sch045
Scheme 46. A series of spiro-1,2,4-triazole-3-thiones 169ag.
Scheme 46. A series of spiro-1,2,4-triazole-3-thiones 169ag.
Molecules 25 03036 sch046
Scheme 47. Synthesis of 1-acetyl-5′-thioxospiro[indoline-3,3′-[1,2,4]triazolidin]-2-one (170).
Scheme 47. Synthesis of 1-acetyl-5′-thioxospiro[indoline-3,3′-[1,2,4]triazolidin]-2-one (170).
Molecules 25 03036 sch047
Scheme 48. Synthesis of spiro-1,2,4-triazole-3-thiones 174aj.
Scheme 48. Synthesis of spiro-1,2,4-triazole-3-thiones 174aj.
Molecules 25 03036 sch048
Scheme 49. Synthesis of spirotriazolethione 179.
Scheme 49. Synthesis of spirotriazolethione 179.
Molecules 25 03036 sch049
Scheme 50. Synthesis of spiro-triazolethiones 183ag.
Scheme 50. Synthesis of spiro-triazolethiones 183ag.
Molecules 25 03036 sch050
Scheme 51. Synthesis of bis-spirotriazolethione 187.
Scheme 51. Synthesis of bis-spirotriazolethione 187.
Molecules 25 03036 sch051
Scheme 52. Synthesis of spiro-[cyclopenta[a]phenanthrene-6,3′-1,2,4triazolidine]-5′-thiones 190ac.
Scheme 52. Synthesis of spiro-[cyclopenta[a]phenanthrene-6,3′-1,2,4triazolidine]-5′-thiones 190ac.
Molecules 25 03036 sch052
Scheme 53. Synthesis of tetrazaspiro[4.5]decane-3-thiones 193ae.
Scheme 53. Synthesis of tetrazaspiro[4.5]decane-3-thiones 193ae.
Molecules 25 03036 sch053
Scheme 54. Synthesis of 1,2,4-triazaspiro[4.5]decane-3-thiones 196af.
Scheme 54. Synthesis of 1,2,4-triazaspiro[4.5]decane-3-thiones 196af.
Molecules 25 03036 sch054
Scheme 55. Formation of triazolothiones 199a,b.
Scheme 55. Formation of triazolothiones 199a,b.
Molecules 25 03036 sch055
Scheme 56. Synthesis of bis-1,2,4-triazoles 205a,b.
Scheme 56. Synthesis of bis-1,2,4-triazoles 205a,b.
Molecules 25 03036 sch056
Scheme 57. Synthesis of 1,2,4-triazole-3-yl)thio)acetate (208).
Scheme 57. Synthesis of 1,2,4-triazole-3-yl)thio)acetate (208).
Molecules 25 03036 sch057
Scheme 58. Synthesis of 1,2,4-triazolethiones 209ag.
Scheme 58. Synthesis of 1,2,4-triazolethiones 209ag.
Molecules 25 03036 sch058
Scheme 59. Synthesis of trisubstituted 1,2,4-triazole 215.
Scheme 59. Synthesis of trisubstituted 1,2,4-triazole 215.
Molecules 25 03036 sch059
Scheme 60. Synthesis of 3-(substituted phenyl)-1,2,4-triazoles 217ai.
Scheme 60. Synthesis of 3-(substituted phenyl)-1,2,4-triazoles 217ai.
Molecules 25 03036 sch060
Scheme 61. Synthesis of 1,2,4-triazol-1-yl)ethyl)thio)-1-(3,4-dichlorobenzyl)-1H-1,2,4-triazole (224).
Scheme 61. Synthesis of 1,2,4-triazol-1-yl)ethyl)thio)-1-(3,4-dichlorobenzyl)-1H-1,2,4-triazole (224).
Molecules 25 03036 sch061
Scheme 62. Synthesis of 1,2,4-triazole-3-yl)thio)acetyl)hydrazinecarbothioamides 227af.
Scheme 62. Synthesis of 1,2,4-triazole-3-yl)thio)acetyl)hydrazinecarbothioamides 227af.
Molecules 25 03036 sch062
Scheme 63. Synthesis of triazolethiones 228ac.
Scheme 63. Synthesis of triazolethiones 228ac.
Molecules 25 03036 sch063
Scheme 64. Synthesis of 1,2,4-triazole-3-yl)thio)acetic acid derivatives 231ae.
Scheme 64. Synthesis of 1,2,4-triazole-3-yl)thio)acetic acid derivatives 231ae.
Molecules 25 03036 sch064
Scheme 65. Synthesis of nucleosides 236 and 237.
Scheme 65. Synthesis of nucleosides 236 and 237.
Molecules 25 03036 sch065
Scheme 66. Synthesis of thio-4-phenyl-4H-1,2,4-triazoles 242ae.
Scheme 66. Synthesis of thio-4-phenyl-4H-1,2,4-triazoles 242ae.
Molecules 25 03036 sch066
Scheme 67. Synthesis of substituted triazoles 245ai.
Scheme 67. Synthesis of substituted triazoles 245ai.
Molecules 25 03036 sch067
Scheme 68. Synthesis of substituted triazoles 248ac.
Scheme 68. Synthesis of substituted triazoles 248ac.
Molecules 25 03036 sch068
Scheme 69. Reaction of triazolethione 249 with pipemidic acid 250.
Scheme 69. Reaction of triazolethione 249 with pipemidic acid 250.
Molecules 25 03036 sch069
Scheme 70. Synthesis of triazolethiones 252- and 253ac.
Scheme 70. Synthesis of triazolethiones 252- and 253ac.
Molecules 25 03036 sch070
Scheme 71. Synthesis S-alkylated triazoles 254ac and 255ac.
Scheme 71. Synthesis S-alkylated triazoles 254ac and 255ac.
Molecules 25 03036 sch071
Scheme 72. Synthesis of triazolebenzylthiol 257.
Scheme 72. Synthesis of triazolebenzylthiol 257.
Molecules 25 03036 sch072
Scheme 73. Synthesis of triazolethiols 259261ac.
Scheme 73. Synthesis of triazolethiols 259261ac.
Molecules 25 03036 sch073
Scheme 74. Mechanism describes formation of triazolethiols 259ac.
Scheme 74. Mechanism describes formation of triazolethiols 259ac.
Molecules 25 03036 sch074
Scheme 75. Synthesis of triazolethiones 262a,b.
Scheme 75. Synthesis of triazolethiones 262a,b.
Molecules 25 03036 sch075
Scheme 76. Synthesis of pyrazolotriazoles 265ad.
Scheme 76. Synthesis of pyrazolotriazoles 265ad.
Molecules 25 03036 sch076
Scheme 77. Synthesis of thiazolotriazoles 267ac.
Scheme 77. Synthesis of thiazolotriazoles 267ac.
Molecules 25 03036 sch077
Scheme 78. Synthesis of triazolo[1,3,4]-thiadiazoles 269ae and 270.
Scheme 78. Synthesis of triazolo[1,3,4]-thiadiazoles 269ae and 270.
Molecules 25 03036 sch078
Scheme 79. Synthesis of thiazolo-1,2,4-triazole carbonitriles 271ae.
Scheme 79. Synthesis of thiazolo-1,2,4-triazole carbonitriles 271ae.
Molecules 25 03036 sch079
Scheme 80. Synthesis of dihydrothiazolo[3,2-b][1,2,4]triazol-5-yl)acetamides 272ae.
Scheme 80. Synthesis of dihydrothiazolo[3,2-b][1,2,4]triazol-5-yl)acetamides 272ae.
Molecules 25 03036 sch080
Scheme 81. Synthesis of thiazolotriazole 275.
Scheme 81. Synthesis of thiazolotriazole 275.
Molecules 25 03036 sch081
Scheme 82. Synthesis of triazolo[1,3,4]-thiadiazoles 276 and 277.
Scheme 82. Synthesis of triazolo[1,3,4]-thiadiazoles 276 and 277.
Molecules 25 03036 sch082
Scheme 83. Synthesis of triazolo[1,3,4]-thiadiazoles 278281ac.
Scheme 83. Synthesis of triazolo[1,3,4]-thiadiazoles 278281ac.
Molecules 25 03036 sch083
Scheme 84. Synthesis of chromone derived by triazolethiadiazines 283ac and triazolo[3,4-b][1,3,4]thiadiazoles 286ac.
Scheme 84. Synthesis of chromone derived by triazolethiadiazines 283ac and triazolo[3,4-b][1,3,4]thiadiazoles 286ac.
Molecules 25 03036 sch084
Scheme 85. Synthesis of triazolothiadiazines 287ai.
Scheme 85. Synthesis of triazolothiadiazines 287ai.
Molecules 25 03036 sch085
Scheme 86. Synthesis of triazoles 290ae.
Scheme 86. Synthesis of triazoles 290ae.
Molecules 25 03036 sch086
Scheme 87. Synthesis of triazolothiadiazines 293.
Scheme 87. Synthesis of triazolothiadiazines 293.
Molecules 25 03036 sch087
Scheme 88. Synthesis of triazolothiadiazines 295aj.
Scheme 88. Synthesis of triazolothiadiazines 295aj.
Molecules 25 03036 sch088
Scheme 89. Synthesis of triazolothiadiazines 296299.
Scheme 89. Synthesis of triazolothiadiazines 296299.
Molecules 25 03036 sch089
Scheme 90. Synthesis of triazolothiadiazine 304.
Scheme 90. Synthesis of triazolothiadiazine 304.
Molecules 25 03036 sch090
Scheme 91. Synthesis of triazolothiadiazines 307.
Scheme 91. Synthesis of triazolothiadiazines 307.
Molecules 25 03036 sch091
Scheme 92. Synthesis of triazolothiadiazines 308ah.
Scheme 92. Synthesis of triazolothiadiazines 308ah.
Molecules 25 03036 sch092
Scheme 93. Synthesis of triazolothiadiazine 311.
Scheme 93. Synthesis of triazolothiadiazine 311.
Molecules 25 03036 sch093
Scheme 94. Synthesis of triazolothiadiazines 314.
Scheme 94. Synthesis of triazolothiadiazines 314.
Molecules 25 03036 sch094
Scheme 95. Synthesis of [1,2,4]triazolo[3,4-b]-[1,3,4]thiadiazines 317ae.
Scheme 95. Synthesis of [1,2,4]triazolo[3,4-b]-[1,3,4]thiadiazines 317ae.
Molecules 25 03036 sch095

Share and Cite

MDPI and ACS Style

Aly, A.A.; A. Hassan, A.; Makhlouf, M.M.; Bräse, S. Chemistry and Biological Activities of 1,2,4-Triazolethiones—Antiviral and Anti-Infective Drugs. Molecules 2020, 25, 3036. https://doi.org/10.3390/molecules25133036

AMA Style

Aly AA, A. Hassan A, Makhlouf MM, Bräse S. Chemistry and Biological Activities of 1,2,4-Triazolethiones—Antiviral and Anti-Infective Drugs. Molecules. 2020; 25(13):3036. https://doi.org/10.3390/molecules25133036

Chicago/Turabian Style

Aly, Ashraf A., Alaa A. Hassan, Maysa M. Makhlouf, and Stefan Bräse. 2020. "Chemistry and Biological Activities of 1,2,4-Triazolethiones—Antiviral and Anti-Infective Drugs" Molecules 25, no. 13: 3036. https://doi.org/10.3390/molecules25133036

APA Style

Aly, A. A., A. Hassan, A., Makhlouf, M. M., & Bräse, S. (2020). Chemistry and Biological Activities of 1,2,4-Triazolethiones—Antiviral and Anti-Infective Drugs. Molecules, 25(13), 3036. https://doi.org/10.3390/molecules25133036

Article Metrics

Back to TopTop